Borderline Personality Disorder

Psychiatric MONDO:0001156 Pathograph 13 Show in embeddings browser Psychiatric Disease Personality Disorder

Borderline personality disorder (BPD) is a psychiatric disorder defined by a long-term pattern of instability in interpersonal relationships, self-image, affect, and impulse control. Presentations can include abandonment sensitivity, recurrent self-injury or suicidal behavior, anger dysregulation, transient paranoid ideation, and stress-related dissociation. Liability is multifactorial; group-level autonomic, stress-axis, inflammatory, and cardiometabolic findings are correlates rather than validated diagnostic biomarkers or established causal pathways.

Ask OpenScientist

Ask a research question about Borderline Personality Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
3
Pathophys.
8
Phenotypes
2
Hypotheses
3
Gaps
13
Pathograph
3
Medical Actions
3
Differentials
1
Datasets
3
Trials
16
References
1
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC
🔗

Mappings

MONDO
MONDO:0001156 borderline personality disorder
skos:exactMatch MONDO
👪

Inheritance

1
Polygenic inheritance HP:0010982
BPD has moderate heritability and familial aggregation but is not modeled as a Mendelian disorder. The register-family design supports distributed inherited liability without identifying a deterministic variant or gene.
Polygenic inheritance
Show evidence (2 references)
DOI:10.1038/s41380-019-0442-0 SUPPORT Human Clinical
"Heritability was estimated at 46% (95% CI = 39–53), and the remaining variance was explained by individually unique environmental factors."
The family model establishes moderate inherited liability; describing it as polygenic is a disease-level interpretation rather than a locus-level result from this study.
DOI:10.1038/s41380-019-0442-0 SUPPORT Human Clinical
"The familial association decreased along with genetic relatedness."
The relatedness gradient supports inherited liability while remaining compatible with a multifactorial rather than Mendelian architecture.
◈

Mechanistic Hypotheses

2
Multifactorial genetic and non-shared-environment liability
multifactorial_liability_model CANONICAL
Evidence balance 1 support
Familial aggregation, moderate heritability, and substantial individually unique environmental variance support a multifactorial liability model. The specific variants, exposures, developmental pathways, and gene-environment relationships remain unresolved.
Pathograph links
Polygenic Liability -> Core Affective and Personality Dysregulation INDIRECT UNKNOWN INTERMEDIATES Genetic and non-shared-environment liability is placed upstream of the defining clinical pattern, but the molecular, developmental, neural, and interpersonal intermediates are unresolved.
Show evidence (1 reference)
DOI:10.1038/s41380-019-0442-0 SUPPORT Human Clinical
"Heritability was estimated at 46% (95% CI = 39–53), and the remaining variance was explained by individually unique environmental factors."
The population-register family model directly supports both inherited and non-shared-environment contributions.
Autonomic, HPA-axis, inflammatory, and cardiometabolic correlate model
autonomic_stress_correlate_model EMERGING
Evidence balance 1 support
Altered heart-rate variability and HPA-axis, inflammatory, and metabolic findings have been proposed as part of BPD biology. Available evidence here is a narrative synthesis of human associations and does not determine whether these findings precede BPD, follow chronic stress and illness, or reflect comorbidity, medication, behavior, or other confounding.
Show evidence (1 reference)
DOI:10.3390/ijms252212286 SUPPORT Human Clinical
"Altered heart rate variability (HRV), reflecting the dysregulation of the autonomic nervous system, is associated with some BPD core symptoms, such as emotional instability and impulsivity."
The review supports association with BPD symptoms but not causal direction.
?

Discussions and Knowledge Gaps

3
Are autonomic, HPA-axis, inflammatory, and cardiometabolic differences causal contributors to BPD, consequences of chronic stress and illness, or correlates of comorbidity, medication, and health behavior?
KNOWLEDGE GAP OPEN gap_bpd_autonomic_stress_causality
Attached to
pathophysiology#Autonomic, Stress-System, and Cardiometabolic Correlates
The available source is a narrative review of heterogeneous human associations. Direction, specificity, temporal precedence, and individual diagnostic utility remain unestablished.
Show evidence (1 reference)
DOI:10.3390/ijms252212286 SUPPORT Human Clinical
"Altered heart rate variability (HRV), reflecting the dysregulation of the autonomic nervous system, is associated with some BPD core symptoms, such as emotional instability and impulsivity."
The source uses associative language and therefore leaves causal direction unresolved.
Which mechanisms and care components convert symptomatic remission into durable social and vocational recovery, and prevent subsequent loss of recovery?
KNOWLEDGE GAP OPEN gap_bpd_symptomatic_vs_functional_recovery
Attached to
progression#Persistent functional vulnerability and possible recurrence
Long follow-up shows that remission of diagnostic symptoms is more common than sustained functional recovery, so symptom-only outcomes can overstate recovery.
Show evidence (1 reference)
PMID:39480146 SUPPORT Human Clinical
"Taken together, the results of this study suggest that sustained symptomatic remission is substantially more common than sustained recovery from BPD."
The prospective cohort directly establishes the outcome gap motivating this question.
Which psychotherapy components and delivery formats produce the most durable benefits for particular BPD presentations beyond common therapeutic factors and bona fide active comparators?
KNOWLEDGE GAP OPEN gap_bpd_comparative_psychotherapy_effectiveness
Attached to
treatments#Evidence-Based Psychotherapy treatments#Mentalization-Based Treatment clinical_trials#NCT06018272
Psychotherapy is first-line and several modalities improve outcomes, but direct active-comparator evidence and treatment-matching evidence remain limited. Current trials should not be interpreted as proof of superiority.
Show evidence (1 reference)
clinicaltrials:NCT06018272 SUPPORT Human Clinical
"Yet, randomized-controlled trials (RCT) on MBT in outpatient settings compared with bona fide treatment (BFT) are still scarce and none has been conducted in Germany."
The trial record explicitly identifies scarcity of MBT comparisons with bona fide outpatient treatment.
⚙

Pathophysiology

3
Polygenic Liability
Distributed inherited susceptibility and individually unique environmental factors contribute to BPD liability. This organism-level node does not assert a single causal gene, exposure, or resolved molecular pathway.
Multifactorial genetic and non-shared-environment liability
Downstream
Core Affective and Personality Dysregulation Genetic and non-shared-environment liability is placed upstream of the defining clinical pattern, but the molecular, developmental, neural, and interpersonal intermediates are unresolved. Multifactorial genetic and non-shared-environment liability
Show evidence (1 reference)
DOI:10.1038/s41380-019-0442-0 SUPPORT Human Clinical
"Heritability was estimated at 46% (95% CI = 39–53), and the remaining variance was explained by individually unique environmental factors."
The Swedish population-register family study supports inherited and individually unique environmental contributions.
Core Affective and Personality Dysregulation
This clinical-state node represents the established long-term pattern of unstable interpersonal relationships and self-image, affective instability, and impulsivity. It is not presented as a localized circuit or molecular mechanism.
Downstream
Emotional Lability Affective instability is a defining manifestation of the aggregate clinical dysregulation state.
Impulsivity Marked impulsivity is a defining manifestation of the aggregate clinical dysregulation state.
Impairment in Personality Functioning Instability of self-image and interpersonal relationships manifests as impaired personality functioning.
Anger Intense anger or difficulty controlling anger can manifest within the BPD clinical pattern.
Dissociation Stress-related dissociative symptoms can occur as a state-dependent manifestation.
Paranoia Transient paranoid ideation can emerge within the BPD clinical pattern, particularly in stressful contexts.
Self-Injurious Behavior Self-injury is part of the severe behavioral spectrum, but the individual routes from affective and interpersonal dysregulation to an episode are heterogeneous.
Suicidal Ideation Suicidal thoughts are clinically important but arise through heterogeneous and incompletely resolved pathways involving distress, crises, and comorbidity.
Show evidence (1 reference)
PMID:41613746 SUPPORT Human Clinical
"Borderline personality disorder (BPD) is characterized by a long-term pattern of instability of interpersonal relationships, unstable self-image, marked impulsivity, and/or affective instability."
The source directly supports the clinical domains represented by this aggregate organism-level node.
Autonomic, Stress-System, and Cardiometabolic Correlates
Human studies summarized in a narrative review report altered heart-rate variability and HPA-axis, inflammatory, metabolic, and cardiovascular measures in BPD. These are retained as provisional group-level correlates, not diagnostic biomarkers or a causal chain to core symptoms.
cellular response to stress GO:0033554 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cellular response to stress (GO:0033554). GO:0033554 is a biological process from the Gene Ontology. ⚠ ABNORMAL inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
DOI:10.3390/ijms252212286 SUPPORT Human Clinical
"Altered heart rate variability (HRV), reflecting the dysregulation of the autonomic nervous system, is associated with some BPD core symptoms, such as emotional instability and impulsivity."
The wording is associative and does not establish whether altered HRV is a cause, consequence, or correlate of symptoms.
DOI:10.3390/ijms252212286 SUPPORT Human Clinical
"Metabolic dysfunctions in BPD, such as elevated body mass index (BMI), high blood pressure, and inflammatory markers like C-reactive protein (CRP), exacerbate these risks."
The narrative review supports group-level cardiometabolic findings but does not validate a BPD-specific causal pathway.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Borderline Personality Disorder Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Nervous System 3
Self-Injurious Behavior HP:0100716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Self-injurious behavior (HP:0100716). HP:0100716 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
DOI:10.1038/s41380-022-01503-z SUPPORT Human Clinical
"Other notable findings from Cox regressions include psychotic disorders (HR 95% CI 24.48 [23.14–25.90]), epilepsy (3.38 [3.08–3.70]), violent crime victimization (7.65 [7.25–8.06]), and self-harm (17.72 [17.27–18.19])."
Nationwide register study supports a strong association between BPD diagnosis and self-harm.
Suicidal Ideation HP:0031589 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Suicidal ideation (HP:0031589). HP:0031589 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38420274 SUPPORT Human Clinical
"These studies looked for treating self-injurious behaviors, suicidal thoughts or ideations, number of visits to emergency services, and frequency of hospital admissions."
Systematic review of BPD DBT trials identifies suicidal thoughts or ideations among treatment targets in BPD trial populations.
Anger HP:0031473 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anger (HP:0031473). HP:0031473 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41613746 SUPPORT Human Clinical
"intense anger or difficulty with anger control"
The practice-assessment article explicitly identifies anger dysregulation as a BPD feature.
Other 5
Emotional Lability HP:0000712 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Emotional lability (HP:0000712). HP:0000712 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41613746 SUPPORT Human Clinical
"Borderline personality disorder (BPD) is characterized by a long-term pattern of instability of interpersonal relationships, unstable self-image, marked impulsivity, and/or affective instability."
The practice-assessment article identifies affective instability as part of the long-term BPD pattern.
Impulsivity HP:0100710 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Impulsivity (HP:0100710). HP:0100710 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41613746 SUPPORT Human Clinical
"Borderline personality disorder (BPD) is characterized by a long-term pattern of instability of interpersonal relationships, unstable self-image, marked impulsivity, and/or affective instability."
The practice-assessment article identifies marked impulsivity as part of the long-term BPD pattern.
Impairment in Personality Functioning HP:0031466 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Impairment in personality functioning (HP:0031466). HP:0031466 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41613746 SUPPORT Human Clinical
"Borderline personality disorder (BPD) is characterized by a long-term pattern of instability of interpersonal relationships, unstable self-image, marked impulsivity, and/or affective instability."
The practice-assessment article directly supports instability in self and interpersonal functioning.
Dissociation HP:0032940 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dissociation (HP:0032940). HP:0032940 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41613746 SUPPORT Human Clinical
"transient paranoid ideation or stress-related dissociative symptoms."
The practice-assessment article directly identifies stress-related dissociative symptoms.
Paranoia HP:0011999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Paranoia (HP:0011999). HP:0011999 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41613746 SUPPORT Human Clinical
"transient paranoid ideation or stress-related dissociative symptoms."
The practice-assessment article directly identifies transient paranoid ideation.
💊

Medical Actions

3
Evidence-Based Psychotherapy
Category: Therapeutic Action: psychotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is psychotherapy (NCIT:C15308). NCIT:C15308 is a clinical intervention from the NCI Thesaurus. Ontology label: Psychotherapy NCIT:C15308
Manualized psychotherapies are first-line treatments for BPD, with several modalities showing benefit relative to treatment as usual.
Target Phenotypes: Impairment in personality functioning HP:0031466 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Impairment in personality functioning (HP:0031466). HP:0031466 is a phenotype from the Human Phenotype Ontology. Emotional lability HP:0000712 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Emotional lability (HP:0000712). HP:0000712 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:37902689 SUPPORT Human Clinical
"Practice guidelines recommend psychotherapies as first-line treatments."
Systematic review states that guidelines recommend psychotherapy as first-line treatment for BPD.
PMID:37902689 SUPPORT Human Clinical
"All commonly used psychotherapies improve BPD severity, symptoms, and functioning."
Systematic review supports psychotherapy effects on BPD severity, symptoms, and functioning.
Dialectical Behavior Therapy
Category: Therapeutic Action: psychotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is psychotherapy (NCIT:C15308). NCIT:C15308 is a clinical intervention from the NCI Thesaurus. Ontology label: Psychotherapy NCIT:C15308
Dialectical behavior therapy is a structured psychotherapy with randomized trial evidence for suicidality, self-injury, mood instability, and related BPD outcomes.
Target Phenotypes: Self-injurious behavior HP:0100716 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Self-injurious behavior (HP:0100716). HP:0100716 is a phenotype from the Human Phenotype Ontology. Impulsivity HP:0100710 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Impulsivity (HP:0100710). HP:0100710 is a phenotype from the Human Phenotype Ontology. Suicidal ideation HP:0031589 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Suicidal ideation (HP:0031589). HP:0031589 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38420274 SUPPORT Human Clinical
"We found 18 RCTs, most of which supported the effectiveness of DBT for BPD."
Systematic review of RCTs supports DBT effectiveness in BPD.
PMID:38420274 SUPPORT Human Clinical
"Most studies revealed that both short-term DBT and standard DBT improved suicidality in BPD patients with small or moderate effect sizes, lasting up to 24 months after the treatment period."
RCT systematic review supports DBT effects on suicidality-related outcomes.
Mentalization-Based Treatment
Category: Therapeutic Action: psychotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is psychotherapy (NCIT:C15308). NCIT:C15308 is a clinical intervention from the NCI Thesaurus. Ontology label: Psychotherapy NCIT:C15308
Mentalization-based treatment is represented as a psychotherapy option that can improve psychiatric symptoms, functioning, and mentalizing capacity.
Target Phenotypes: Impairment in personality functioning HP:0031466 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Impairment in personality functioning (HP:0031466). HP:0031466 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
DOI:10.1186/s12888-024-05865-2 SUPPORT Human Clinical
"Several studies have observed that mentalization-based treatment (MBT) is an effective treatment for borderline personality disorder (BPD), but its effectiveness for other personality disorders (PDs) has hardly been examined."
Naturalistic study abstract supports MBT relevance to BPD, but the study also includes non-BPD personality disorders, so support is partial.
DOI:10.1186/s12888-024-05865-2 SUPPORT Human Clinical
"These results suggest that MBT coincides with symptomatic and functional improvement across a broad range of PDs and shows that MBT is associated with improvements in mentalizing capacity."
Supports symptomatic and functional improvement during MBT, while the non-experimental design and mixed PD cohort make this partial for BPD specifically.
🌍

Environmental Factors

1
Non-shared environmental contribution and reported early trauma
Family modeling attributes substantial residual variance to individually unique environmental factors but does not identify particular exposures. Early trauma has been proposed as relevant to stress-system findings, yet the cited narrative review does not establish that trauma is necessary, sufficient, or causally specific to BPD.
Show evidence (2 references)
DOI:10.1038/s41380-019-0442-0 SUPPORT Human Clinical
"Heritability was estimated at 46% (95% CI = 39–53), and the remaining variance was explained by individually unique environmental factors."
Register-based family model supports individually unique environmental contribution to BPD liability.
DOI:10.3390/ijms252212286 SUPPORT Human Clinical
"Dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, often stemming from early trauma, contributes to chronic inflammation and elevated allostatic load, which further increases cardiovascular risk."
The narrative review proposes a trauma-to-stress-system route, but this wording does not establish causal specificity or direction.
🔬

Diagnosis

2
Longitudinal psychiatric diagnostic assessment (A persistent pattern of instability across core personality, affective, interpersonal, and behavioral domains, assessed in longitudinal context.)
Diagnosis is clinical and should evaluate the long-term pattern across interpersonal relationships, self-image and identity, affect regulation, impulse control, anger, dissociation, paranoia, self-injury, suicidality, distress, and functional impairment. A single symptom or crisis presentation is insufficient to characterize the enduring pattern.
psychiatrist evaluation NCIT:C124351 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:41613746 SUPPORT Human Clinical
"Borderline personality disorder (BPD) is characterized by a long-term pattern of instability of interpersonal relationships, unstable self-image, marked impulsivity, and/or affective instability."
The practice-assessment article identifies the longitudinal domains that anchor clinical diagnosis.
PMID:29795363 SUPPORT Human Clinical
"Thus, clinicians need to actively enquire about the central issues of interpersonal relations and unstable identity."
The disease primer directly recommends active inquiry into central interpersonal and identity features.
Comorbidity, differential, functioning, and safety assessment (Assessment documents comorbidity, impairment, self-harm and suicide risk, and whether overlapping symptoms are better explained by or coexist with another disorder.)
Assess co-occurring psychiatric disorders, episodic mood syndromes, trauma-related symptoms, substance use, social and vocational functioning, current and past self-injury, suicidal thoughts and behavior, and immediate safety needs. Bipolar disorder, PTSD, and other personality disorders must be considered rather than assumed to be mutually exclusive.
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:41613746 SUPPORT Human Clinical
"BPD is associated with substantial lifetime burdens and psychosocial impairments, including high rates of co-occurring psychiatric disorders; disruptions in interpersonal relationships, school, work, and housing; and suicide attempts and nonsuicidal self-injury."
The documented comorbidity, functional disruption, and self-harm burden supports systematic assessment of these domains.
PMID:26401313 SUPPORT Human Clinical
"The differential impact of these disorders occurring alone versus in comorbid form highlights the importance of diagnosing both BPD and PTSD and attending to lifetime comorbidity."
Population evidence directly supports diagnosing comorbid PTSD rather than forcing a single-disorder explanation.
📈

Progression

2
Long-term symptomatic improvement and remission
Prospective adult studies generally show symptomatic improvement over time, although estimates vary with cohort, treatment exposure, remission definition, and follow-up duration. A meta-analysis of 11 studies found long-term diagnostic remission in 50%-70% of participants.
Show evidence (2 references)
PMID:30599336 SUPPORT Human Clinical
"Between 50% and 70% of the BPD patients achieved remission in the long-term."
The prospective-study meta-analysis directly quantifies long-term diagnostic remission.
PMID:29795363 SUPPORT Human Clinical
"Most patients gradually enter symptomatic remission, and their rate of remission can be accelerated by evidence-based psychosocial treatments."
The disease primer describes gradual symptomatic remission and the role of evidence-based psychosocial care.
Persistent functional vulnerability and possible recurrence
Symptomatic remission does not guarantee durable social and vocational recovery. In one intensively assessed inpatient cohort followed for 24 years, sustained remission was more common than sustained recovery, and loss of recovery was more common than symptomatic recurrence; those cohort-specific percentages should not be generalized as population rates.
Show evidence (2 references)
PMID:39480146 SUPPORT Human Clinical
"Taken together, the results of this study suggest that sustained symptomatic remission is substantially more common than sustained recovery from BPD."
The 24-year prospective cohort distinguishes symptom remission from the stricter outcome of remission plus good social and vocational functioning.
PMID:39480146 SUPPORT Human Clinical
"They also suggest that loss of sustained recovery is more common than symptomatic recurrences for those with BPD."
Long follow-up supports continued attention to functioning even after diagnostic symptoms improve.
📊

Prevalence

1
General population
Point Prevalence 1800.0 per 100,000 >1 in 1,000
Show evidence (1 reference)
PMID:37902689 SUPPORT Human Clinical
"Borderline personality disorder (BPD) is the most common personality disorder, affecting 1.8% of the general population, 10% of psychiatric outpatients, and 15%-25% of psychiatric inpatients."
Systematic review abstract gives population and psychiatric-care prevalence estimates for BPD.
⚖️

Clinical Burden

High
BPD can substantially disrupt relationships, education, employment, and housing and is associated with recurrent crises, nonsuicidal self-injury, suicide attempts, psychiatric comorbidity, and high health-care and social costs. Functional impairment can persist after symptomatic remission.
Show evidence (2 references)
PMID:41613746 SUPPORT Human Clinical
"BPD is associated with substantial lifetime burdens and psychosocial impairments, including high rates of co-occurring psychiatric disorders; disruptions in interpersonal relationships, school, work, and housing; and suicide attempts and nonsuicidal self-injury."
The APA practice-assessment publication directly describes the lifetime, functional, comorbidity, and self-harm burden.
PMID:29795363 SUPPORT Human Clinical
"Caretakers are often intimidated or alienated by patients with borderline personality disorder (BPD), compounding the clinical challenges posed by the severe morbidity, high social costs and substantial prevalence of this disorder in many health-care settings."
The disease primer characterizes BPD as having severe morbidity and high social costs.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Borderline Personality Disorder:

Bipolar Disorder MONDO:0004985
Overlapping Features Bipolar disorder can overlap with BPD through mood instability, impulsive behavior, and recurrent crises.
Distinguishing Features
  • Bipolar disorder is distinguished by discrete manic, hypomanic, or depressive episodes; BPD typically shows rapid affective reactivity tied to interpersonal stressors and persistent personality-function impairment.
Show evidence (1 reference)
PMID:11684137 SUPPORT Human Clinical
"The aim of this study was to compare impulsivity, affective lability and intensity in patients with borderline personality and bipolar II disorder and in subjects with neither of these diagnoses."
Comparative clinical evidence supports bipolar disorder as a differential diagnosis for BPD when affective lability and impulsivity overlap.
Post-Traumatic Stress Disorder MONDO:0005146
Overlapping Features PTSD and BPD can share trauma history, affective dysregulation, avoidance, and dissociative symptoms.
Distinguishing Features
  • PTSD centers on trauma re-experiencing, avoidance, and hyperarousal after a traumatic event; BPD requires enduring instability in self, relationships, affect, and impulse control.
Show evidence (1 reference)
PMID:26401313 SUPPORT Human Clinical
"The differential impact of these disorders occurring alone versus in comorbid form highlights the importance of diagnosing both BPD and PTSD and attending to lifetime comorbidity."
Population-based evidence supports assessing PTSD separately when BPD and trauma-related symptoms overlap.
Antisocial Personality Disorder Not Yet Curated MONDO:0001164
Overlapping Features Antisocial personality disorder can overlap with BPD through impulsivity, interpersonal conflict, and risk-taking behavior.
Distinguishing Features
  • Antisocial personality disorder is distinguished by pervasive disregard for others' rights, deceitfulness, and conduct-problem history; BPD is more defined by abandonment sensitivity, affective instability, self-harm, and identity disturbance.
Show evidence (1 reference)
PMID:23514180 SUPPORT Human Clinical
"Impulsivity is a shared criterion for the diagnosis of antisocial and borderline personality disorders, and this link may account for the high comorbidity rates between the two disorders."
Differential-diagnosis evidence supports antisocial personality disorder as a relevant comparator where impulsivity and interpersonal conflict overlap.
📊

Related Datasets

1
Aberrant methylation of gene associated CpG sites occurs in borderline personality disorder geo:GSE52222
Borderline personality disorder (BPD) is a complex psychiatric disease with an increased impact in the last years. While the diagnosis and therapy are well established, little is known on the pathogenesis of borderline personality disorder. Previously, a significant increase in DNA methylation of relevant neuropsychiatric genes in BPD patients has been reported. In our study we performed genome wide methylation analysis and revealed specific CpG sites that exhibited increased methylation in 26 BPD patients compared to 11 healthy controls.
human METHYLATION n=36
PMID:24367640
Identified by GEO DataSets index search for Borderline Personality Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
🔬

Clinical Trials

3
NCT06018272 NOT_APPLICABLE RECRUITING
Five-site German randomized trial comparing 12 months of outpatient mentalization-based treatment with bona fide psychodynamic or cognitive behavioral psychotherapy. Crisis events involving nonsuicidal self-injury or suicide attempts are the primary outcome. The registry listed estimated enrollment of 304 when checked on 2026-07-24; an active trial record does not establish comparative efficacy.
Target Phenotypes: Self-injurious behavior HP:0100716 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Self-injurious behavior (HP:0100716). HP:0100716 is a phenotype from the Human Phenotype Ontology. Impairment in personality functioning HP:0031466 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Impairment in personality functioning (HP:0031466). HP:0031466 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT06018272 SUPPORT Human Clinical
"The primary objective of this RCT is to investigate whether outpatient MBT is more effective in the reduction of crisis events (incidences of NSSI and suicide attempts) compared with BFT (namely psychodynamic or cognitive-behavioural psychotherapy) in Germany."
The registry directly states the randomized comparison and primary crisis outcome.
NCT06458933 PHASE_II RECRUITING
Randomized comparison of the 12-session Sage couple intervention with separate supportive individual psychotherapy for a person with BPD and their intimate partner. The registry listed 152 couples (304 participants) when checked on 2026-07-24. This is an investigational relationship-focused intervention, not established care.
Target Phenotypes: Impairment in personality functioning HP:0031466 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Impairment in personality functioning (HP:0031466). HP:0031466 is a phenotype from the Human Phenotype Ontology. Emotional lability HP:0000712 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Emotional lability (HP:0000712). HP:0000712 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT06458933 SUPPORT Human Clinical
"The study will examine if Sage is more efficacious than SIP in improving BPD symptoms (primary outcome), as well as relationship conflict and partner mental health (secondary outcomes), as well as a range of other outcomes, from pre- to post-intervention, and post-intervention to follow-up."
The registry directly describes the experimental couple intervention, active comparator, and outcomes.
NCT06446765 PHASE_II RECRUITING
Triple-masked randomized study of one mindfulness-based real-time fMRI neurofeedback session versus control neurofeedback, followed in both groups by 20 weeks of remote DBT skills training. The registry listed estimated enrollment of 150 when checked on 2026-07-24. Neurofeedback augmentation remains experimental.
Target Phenotypes: Emotional lability HP:0000712 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Emotional lability (HP:0000712). HP:0000712 is a phenotype from the Human Phenotype Ontology. Impulsivity HP:0100710 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Impulsivity (HP:0100710). HP:0100710 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT06446765 SUPPORT Human Clinical
"The purpose of this study is to test the ability of mindfulness-based real time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to increase the benefits of evidence-based psychotherapy for adults with Borderline Personality Disorder (BPD)."
The registry directly identifies neurofeedback as an experimental augmentation of evidence-based psychotherapy.
{ }

Source YAML

click to show 
name: Borderline Personality Disorder
creation_date: "2026-04-28T00:00:00Z"
category: Psychiatric
description: >-
  Borderline personality disorder (BPD) is a psychiatric disorder defined by a
  long-term pattern of instability in interpersonal relationships, self-image,
  affect, and impulse control. Presentations can include abandonment
  sensitivity, recurrent self-injury or suicidal behavior, anger dysregulation,
  transient paranoid ideation, and stress-related dissociation. Liability is
  multifactorial; group-level autonomic, stress-axis, inflammatory, and
  cardiometabolic findings are correlates rather than validated diagnostic
  biomarkers or established causal pathways.
disease_term:
  preferred_term: borderline personality disorder
  term:
    id: MONDO:0001156
    label: borderline personality disorder
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0001156
      label: borderline personality disorder
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
parents:
- Psychiatric Disease
- Personality Disorder
synonyms:
- Emotionally unstable personality disorder
- Borderline pattern
prevalence:
- population: General population
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1800.0
  percentage: 1.8
  evidence:
  - reference: PMID:37902689
    reference_title: "Psychotherapies for the treatment of borderline personality disorder: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Borderline personality disorder (BPD) is the most common personality
      disorder, affecting 1.8% of the general population, 10% of psychiatric
      outpatients, and 15%-25% of psychiatric inpatients.
    explanation: >-
      Systematic review abstract gives population and psychiatric-care
      prevalence estimates for BPD.
progression:
- phase: Long-term symptomatic improvement and remission
  notes: >-
    Prospective adult studies generally show symptomatic improvement over time,
    although estimates vary with cohort, treatment exposure, remission
    definition, and follow-up duration. A meta-analysis of 11 studies found
    long-term diagnostic remission in 50%-70% of participants.
  evidence:
  - reference: PMID:30599336
    reference_title: "Long-term clinical and functional course of borderline personality disorder: A meta-analysis of prospective studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Between 50% and 70% of the BPD patients achieved remission in the
      long-term.
    explanation: >-
      The prospective-study meta-analysis directly quantifies long-term
      diagnostic remission.
  - reference: PMID:29795363
    reference_title: Borderline personality disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most patients gradually enter symptomatic remission, and their rate of
      remission can be accelerated by evidence-based psychosocial treatments.
    explanation: >-
      The disease primer describes gradual symptomatic remission and the role
      of evidence-based psychosocial care.
- phase: Persistent functional vulnerability and possible recurrence
  notes: >-
    Symptomatic remission does not guarantee durable social and vocational
    recovery. In one intensively assessed inpatient cohort followed for 24
    years, sustained remission was more common than sustained recovery, and
    loss of recovery was more common than symptomatic recurrence; those
    cohort-specific percentages should not be generalized as population rates.
  evidence:
  - reference: PMID:39480146
    reference_title: "Sustained Symptomatic Remission and Recovery and Their Loss Among Patients With Borderline Personality Disorder and Patients With Other Types of Personality Disorders: A 24-Year Prospective Follow-Up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Taken together, the results of this study suggest that sustained
      symptomatic remission is substantially more common than sustained
      recovery from BPD.
    explanation: >-
      The 24-year prospective cohort distinguishes symptom remission from the
      stricter outcome of remission plus good social and vocational
      functioning.
  - reference: PMID:39480146
    reference_title: "Sustained Symptomatic Remission and Recovery and Their Loss Among Patients With Borderline Personality Disorder and Patients With Other Types of Personality Disorders: A 24-Year Prospective Follow-Up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They also suggest that loss of sustained recovery is more common than
      symptomatic recurrences for those with BPD.
    explanation: >-
      Long follow-up supports continued attention to functioning even after
      diagnostic symptoms improve.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    BPD can substantially disrupt relationships, education, employment, and
    housing and is associated with recurrent crises, nonsuicidal self-injury,
    suicide attempts, psychiatric comorbidity, and high health-care and social
    costs. Functional impairment can persist after symptomatic remission.
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BPD is associated with substantial lifetime burdens and psychosocial
      impairments, including high rates of co-occurring psychiatric disorders;
      disruptions in interpersonal relationships, school, work, and housing;
      and suicide attempts and nonsuicidal self-injury.
    explanation: >-
      The APA practice-assessment publication directly describes the lifetime,
      functional, comorbidity, and self-harm burden.
  - reference: PMID:29795363
    reference_title: Borderline personality disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Caretakers are often intimidated or alienated by patients with borderline
      personality disorder (BPD), compounding the clinical challenges posed by
      the severe morbidity, high social costs and substantial prevalence of
      this disorder in many health-care settings.
    explanation: >-
      The disease primer characterizes BPD as having severe morbidity and high
      social costs.
inheritance:
- name: Polygenic inheritance
  inheritance_term:
    preferred_term: Polygenic inheritance
    term:
      id: HP:0010982
      label: Polygenic inheritance
  description: >-
    BPD has moderate heritability and familial aggregation but is not modeled
    as a Mendelian disorder. The register-family design supports distributed
    inherited liability without identifying a deterministic variant or gene.
  evidence:
  - reference: DOI:10.1038/s41380-019-0442-0
    reference_title: "Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Heritability was estimated at 46% (95% CI = 39–53), and the remaining
      variance was explained by individually unique environmental factors.
    explanation: >-
      The family model establishes moderate inherited liability; describing it
      as polygenic is a disease-level interpretation rather than a locus-level
      result from this study.
  - reference: DOI:10.1038/s41380-019-0442-0
    reference_title: "Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The familial association decreased along with genetic relatedness.
    explanation: >-
      The relatedness gradient supports inherited liability while remaining
      compatible with a multifactorial rather than Mendelian architecture.
mechanistic_hypotheses:
- hypothesis_group_id: multifactorial_liability_model
  hypothesis_label: Multifactorial genetic and non-shared-environment liability
  status: CANONICAL
  description: >-
    Familial aggregation, moderate heritability, and substantial individually
    unique environmental variance support a multifactorial liability model.
    The specific variants, exposures, developmental pathways, and
    gene-environment relationships remain unresolved.
  evidence:
  - reference: DOI:10.1038/s41380-019-0442-0
    reference_title: "Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Heritability was estimated at 46% (95% CI = 39–53), and the remaining
      variance was explained by individually unique environmental factors.
    explanation: >-
      The population-register family model directly supports both inherited
      and non-shared-environment contributions.
- hypothesis_group_id: autonomic_stress_correlate_model
  hypothesis_label: Autonomic, HPA-axis, inflammatory, and cardiometabolic correlate model
  status: EMERGING
  description: >-
    Altered heart-rate variability and HPA-axis, inflammatory, and metabolic
    findings have been proposed as part of BPD biology. Available evidence here
    is a narrative synthesis of human associations and does not determine
    whether these findings precede BPD, follow chronic stress and illness, or
    reflect comorbidity, medication, behavior, or other confounding.
  evidence:
  - reference: DOI:10.3390/ijms252212286
    reference_title: "Metabolic Dysfunctions, Dysregulation of the Autonomic Nervous System, and Echocardiographic Parameters in Borderline Personality Disorder: A Narrative Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Altered heart rate variability (HRV), reflecting the dysregulation of the
      autonomic nervous system, is associated with some BPD core symptoms, such
      as emotional instability and impulsivity.
    explanation: >-
      The review supports association with BPD symptoms but not causal
      direction.
pathophysiology:
- name: Polygenic Liability
  description: >-
    Distributed inherited susceptibility and individually unique environmental
    factors contribute to BPD liability. This organism-level node does not
    assert a single causal gene, exposure, or resolved molecular pathway.
  mechanism_confidence: ESTABLISHED
  biological_scale: ORGANISM
  downstream:
  - target: Core Affective and Personality Dysregulation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - multifactorial_liability_model
    description: >-
      Genetic and non-shared-environment liability is placed upstream of the
      defining clinical pattern, but the molecular, developmental, neural, and
      interpersonal intermediates are unresolved.
    evidence:
    - reference: DOI:10.1038/s41380-019-0442-0
      reference_title: "Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The familial association decreased along with genetic relatedness.
      explanation: >-
        Familial aggregation supports upstream liability, while this design
        does not resolve a direct pathway to the clinical syndrome.
  evidence:
  - reference: DOI:10.1038/s41380-019-0442-0
    reference_title: "Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Heritability was estimated at 46% (95% CI = 39–53), and the remaining
      variance was explained by individually unique environmental factors.
    explanation: >-
      The Swedish population-register family study supports inherited and
      individually unique environmental contributions.
- name: Core Affective and Personality Dysregulation
  description: >-
    This clinical-state node represents the established long-term pattern of
    unstable interpersonal relationships and self-image, affective instability,
    and impulsivity. It is not presented as a localized circuit or molecular
    mechanism.
  mechanism_confidence: ESTABLISHED
  biological_scale: ORGANISM
  downstream:
  - target: Emotional Lability
    causal_link_type: DIRECT
    description: >-
      Affective instability is a defining manifestation of the aggregate
      clinical dysregulation state.
    evidence:
    - reference: PMID:41613746
      reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Borderline personality disorder (BPD) is characterized by a long-term
        pattern of instability of interpersonal relationships, unstable
        self-image, marked impulsivity, and/or affective instability.
      explanation: >-
        The practice-assessment article directly identifies affective
        instability within the defining long-term pattern.
  - target: Impulsivity
    causal_link_type: DIRECT
    description: >-
      Marked impulsivity is a defining manifestation of the aggregate clinical
      dysregulation state.
    evidence:
    - reference: PMID:41613746
      reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Borderline personality disorder (BPD) is characterized by a long-term
        pattern of instability of interpersonal relationships, unstable
        self-image, marked impulsivity, and/or affective instability.
      explanation: >-
        The practice-assessment article directly includes marked impulsivity in
        the defining pattern.
  - target: Impairment in Personality Functioning
    causal_link_type: DIRECT
    description: >-
      Instability of self-image and interpersonal relationships manifests as
      impaired personality functioning.
    evidence:
    - reference: PMID:41613746
      reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Borderline personality disorder (BPD) is characterized by a long-term
        pattern of instability of interpersonal relationships, unstable
        self-image, marked impulsivity, and/or affective instability.
      explanation: >-
        Interpersonal and self-image instability directly support the
        personality-function phenotype.
  - target: Anger
    causal_link_type: DIRECT
    description: >-
      Intense anger or difficulty controlling anger can manifest within the BPD
      clinical pattern.
    evidence:
    - reference: PMID:41613746
      reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: intense anger or difficulty with anger control
      explanation: >-
        The practice-assessment article identifies anger dysregulation as a BPD
        feature.
  - target: Dissociation
    causal_link_type: DIRECT
    description: >-
      Stress-related dissociative symptoms can occur as a state-dependent
      manifestation.
    evidence:
    - reference: PMID:41613746
      reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: transient paranoid ideation or stress-related dissociative symptoms.
      explanation: >-
        The practice-assessment article explicitly identifies stress-related
        dissociation.
  - target: Paranoia
    causal_link_type: DIRECT
    description: >-
      Transient paranoid ideation can emerge within the BPD clinical pattern,
      particularly in stressful contexts.
    evidence:
    - reference: PMID:41613746
      reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: transient paranoid ideation or stress-related dissociative symptoms.
      explanation: >-
        The practice-assessment article explicitly identifies transient
        paranoid ideation.
  - target: Self-Injurious Behavior
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Self-injury is part of the severe behavioral spectrum, but the individual
      routes from affective and interpersonal dysregulation to an episode are
      heterogeneous.
    evidence:
    - reference: PMID:41613746
      reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: recurrent self-injurious or suicidal behavior
      explanation: >-
        The source establishes recurrent self-injury as a BPD feature but does
        not establish one direct causal route from core dysregulation.
  - target: Suicidal Ideation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Suicidal thoughts are clinically important but arise through heterogeneous
      and incompletely resolved pathways involving distress, crises, and
      comorbidity.
    evidence:
    - reference: PMID:38420274
      reference_title: "Efficacy of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder: A Systematic Review of Randomized Controlled Trials."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These studies looked for treating self-injurious behaviors, suicidal
        thoughts or ideations, number of visits to emergency services, and
        frequency of hospital admissions.
      explanation: >-
        Trials establish suicidal ideation as a BPD treatment target, but they
        do not resolve a direct causal path from core dysregulation.
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Borderline personality disorder (BPD) is characterized by a long-term
      pattern of instability of interpersonal relationships, unstable
      self-image, marked impulsivity, and/or affective instability.
    explanation: >-
      The source directly supports the clinical domains represented by this
      aggregate organism-level node.
- name: Autonomic, Stress-System, and Cardiometabolic Correlates
  description: >-
    Human studies summarized in a narrative review report altered heart-rate
    variability and HPA-axis, inflammatory, metabolic, and cardiovascular
    measures in BPD. These are retained as provisional group-level correlates,
    not diagnostic biomarkers or a causal chain to core symptoms.
  mechanism_confidence: PROVISIONAL
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: cellular response to stress
    term:
      id: GO:0033554
      label: cellular response to stress
    modifier: ABNORMAL
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: DOI:10.3390/ijms252212286
    reference_title: "Metabolic Dysfunctions, Dysregulation of the Autonomic Nervous System, and Echocardiographic Parameters in Borderline Personality Disorder: A Narrative Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Altered heart rate variability (HRV), reflecting the dysregulation of the
      autonomic nervous system, is associated with some BPD core symptoms, such
      as emotional instability and impulsivity.
    explanation: >-
      The wording is associative and does not establish whether altered HRV is
      a cause, consequence, or correlate of symptoms.
  - reference: DOI:10.3390/ijms252212286
    reference_title: "Metabolic Dysfunctions, Dysregulation of the Autonomic Nervous System, and Echocardiographic Parameters in Borderline Personality Disorder: A Narrative Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Metabolic dysfunctions in BPD, such as elevated body mass index (BMI),
      high blood pressure, and inflammatory markers like C-reactive protein
      (CRP), exacerbate these risks.
    explanation: >-
      The narrative review supports group-level cardiometabolic findings but
      does not validate a BPD-specific causal pathway.
phenotypes:
- name: Emotional Lability
  category: Psychiatric
  diagnostic: true
  description: Rapid shifts in affect and intense emotional instability.
  phenotype_term:
    preferred_term: Emotional lability
    term:
      id: HP:0000712
      label: Emotional lability
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Borderline personality disorder (BPD) is characterized by a long-term
      pattern of instability of interpersonal relationships, unstable
      self-image, marked impulsivity, and/or affective instability.
    explanation: >-
      The practice-assessment article identifies affective instability as part
      of the long-term BPD pattern.
- name: Impulsivity
  category: Psychiatric
  diagnostic: true
  description: Impulsive behavior is a core clinical feature.
  phenotype_term:
    preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Borderline personality disorder (BPD) is characterized by a long-term
      pattern of instability of interpersonal relationships, unstable
      self-image, marked impulsivity, and/or affective instability.
    explanation: >-
      The practice-assessment article identifies marked impulsivity as part of
      the long-term BPD pattern.
- name: Self-Injurious Behavior
  category: Psychiatric
  description: Self-harm risk is markedly elevated in diagnosed BPD.
  phenotype_term:
    preferred_term: Self-injurious behavior
    term:
      id: HP:0100716
      label: Self-injurious behavior
  evidence:
  - reference: DOI:10.1038/s41380-022-01503-z
    reference_title: "Borderline personality disorder: associations with psychiatric disorders, somatic illnesses, trauma, and adverse behaviors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other notable findings from Cox regressions include psychotic disorders
      (HR 95% CI 24.48 [23.14–25.90]), epilepsy (3.38 [3.08–3.70]), violent
      crime victimization (7.65 [7.25–8.06]), and self-harm (17.72
      [17.27–18.19]).
    explanation: >-
      Nationwide register study supports a strong association between BPD
      diagnosis and self-harm.
- name: Suicidal Ideation
  category: Psychiatric
  description: >-
    Suicidal thoughts and ideation are clinically important treatment targets
    in BPD.
  phenotype_term:
    preferred_term: Suicidal ideation
    term:
      id: HP:0031589
      label: Suicidal ideation
  evidence:
  - reference: PMID:38420274
    reference_title: "Efficacy of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder: A Systematic Review of Randomized Controlled Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These studies looked for treating self-injurious behaviors, suicidal
      thoughts or ideations, number of visits to emergency services, and
      frequency of hospital admissions.
    explanation: >-
      Systematic review of BPD DBT trials identifies suicidal thoughts or
      ideations among treatment targets in BPD trial populations.
- name: Impairment in Personality Functioning
  category: Psychiatric
  diagnostic: true
  description: BPD includes disturbed self/identity and interpersonal functioning.
  phenotype_term:
    preferred_term: Impairment in personality functioning
    term:
      id: HP:0031466
      label: Impairment in personality functioning
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Borderline personality disorder (BPD) is characterized by a long-term
      pattern of instability of interpersonal relationships, unstable
      self-image, marked impulsivity, and/or affective instability.
    explanation: >-
      The practice-assessment article directly supports instability in self and
      interpersonal functioning.
- name: Anger
  category: Psychiatric
  diagnostic: true
  description: Intense anger or difficulty controlling anger can occur in BPD.
  phenotype_term:
    preferred_term: Anger
    term:
      id: HP:0031473
      label: Anger
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: intense anger or difficulty with anger control
    explanation: >-
      The practice-assessment article explicitly identifies anger
      dysregulation as a BPD feature.
- name: Dissociation
  category: Psychiatric
  diagnostic: true
  description: Stress-related dissociative symptoms can occur transiently.
  phenotype_term:
    preferred_term: Dissociation
    term:
      id: HP:0032940
      label: Dissociation
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: transient paranoid ideation or stress-related dissociative symptoms.
    explanation: >-
      The practice-assessment article directly identifies stress-related
      dissociative symptoms.
- name: Paranoia
  category: Psychiatric
  diagnostic: true
  description: Transient paranoid ideation can occur, particularly under stress.
  phenotype_term:
    preferred_term: Paranoia
    term:
      id: HP:0011999
      label: Paranoia
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: transient paranoid ideation or stress-related dissociative symptoms.
    explanation: >-
      The practice-assessment article directly identifies transient paranoid
      ideation.
environmental:
- name: Non-shared environmental contribution and reported early trauma
  presence: Associated contribution; specific causal exposures remain unresolved
  description: >-
    Family modeling attributes substantial residual variance to individually
    unique environmental factors but does not identify particular exposures.
    Early trauma has been proposed as relevant to stress-system findings, yet
    the cited narrative review does not establish that trauma is necessary,
    sufficient, or causally specific to BPD.
  effect: Possible contribution to multifactorial liability
  evidence:
  - reference: DOI:10.1038/s41380-019-0442-0
    reference_title: "Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Heritability was estimated at 46% (95% CI = 39–53), and the remaining
      variance was explained by individually unique environmental factors.
    explanation: >-
      Register-based family model supports individually unique environmental
      contribution to BPD liability.
  - reference: DOI:10.3390/ijms252212286
    reference_title: "Metabolic Dysfunctions, Dysregulation of the Autonomic Nervous System, and Echocardiographic Parameters in Borderline Personality Disorder: A Narrative Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, often
      stemming from early trauma, contributes to chronic inflammation and
      elevated allostatic load, which further increases cardiovascular risk.
    explanation: >-
      The narrative review proposes a trauma-to-stress-system route, but this
      wording does not establish causal specificity or direction.
treatments:
- name: Evidence-Based Psychotherapy
  action_category: THERAPEUTIC
  description: >-
    Manualized psychotherapies are first-line treatments for BPD, with several
    modalities showing benefit relative to treatment as usual.
  treatment_term:
    preferred_term: psychotherapy
    term:
      id: NCIT:C15308
      label: Psychotherapy
  target_phenotypes:
  - preferred_term: Impairment in personality functioning
    term:
      id: HP:0031466
      label: Impairment in personality functioning
  - preferred_term: Emotional lability
    term:
      id: HP:0000712
      label: Emotional lability
  evidence:
  - reference: PMID:37902689
    reference_title: "Psychotherapies for the treatment of borderline personality disorder: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Practice guidelines recommend psychotherapies as first-line treatments.
    explanation: >-
      Systematic review states that guidelines recommend psychotherapy as
      first-line treatment for BPD.
  - reference: PMID:37902689
    reference_title: "Psychotherapies for the treatment of borderline personality disorder: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All commonly used psychotherapies improve BPD severity, symptoms, and
      functioning.
    explanation: >-
      Systematic review supports psychotherapy effects on BPD severity,
      symptoms, and functioning.
- name: Dialectical Behavior Therapy
  action_category: THERAPEUTIC
  description: >-
    Dialectical behavior therapy is a structured psychotherapy with randomized
    trial evidence for suicidality, self-injury, mood instability, and related
    BPD outcomes.
  treatment_term:
    preferred_term: psychotherapy
    term:
      id: NCIT:C15308
      label: Psychotherapy
  target_phenotypes:
  - preferred_term: Self-injurious behavior
    term:
      id: HP:0100716
      label: Self-injurious behavior
  - preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  - preferred_term: Suicidal ideation
    term:
      id: HP:0031589
      label: Suicidal ideation
  evidence:
  - reference: PMID:38420274
    reference_title: "Efficacy of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder: A Systematic Review of Randomized Controlled Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found 18 RCTs, most of which supported the effectiveness of DBT for
      BPD.
    explanation: >-
      Systematic review of RCTs supports DBT effectiveness in BPD.
  - reference: PMID:38420274
    reference_title: "Efficacy of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder: A Systematic Review of Randomized Controlled Trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most studies revealed that both short-term DBT and standard DBT improved
      suicidality in BPD patients with small or moderate effect sizes, lasting
      up to 24 months after the treatment period.
    explanation: >-
      RCT systematic review supports DBT effects on suicidality-related outcomes.
- name: Mentalization-Based Treatment
  action_category: THERAPEUTIC
  description: >-
    Mentalization-based treatment is represented as a psychotherapy option that
    can improve psychiatric symptoms, functioning, and mentalizing capacity.
  treatment_term:
    preferred_term: psychotherapy
    term:
      id: NCIT:C15308
      label: Psychotherapy
  target_phenotypes:
  - preferred_term: Impairment in personality functioning
    term:
      id: HP:0031466
      label: Impairment in personality functioning
  evidence:
  - reference: DOI:10.1186/s12888-024-05865-2
    reference_title: "Mentalization based treatment for a broad range of personality disorders: a naturalistic study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Several studies have observed that mentalization-based treatment (MBT) is
      an effective treatment for borderline personality disorder (BPD), but its
      effectiveness for other personality disorders (PDs) has hardly been
      examined.
    explanation: >-
      Naturalistic study abstract supports MBT relevance to BPD, but the study
      also includes non-BPD personality disorders, so support is partial.
  - reference: DOI:10.1186/s12888-024-05865-2
    reference_title: "Mentalization based treatment for a broad range of personality disorders: a naturalistic study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These results suggest that MBT coincides with symptomatic and functional
      improvement across a broad range of PDs and shows that MBT is associated
      with improvements in mentalizing capacity.
    explanation: >-
      Supports symptomatic and functional improvement during MBT, while the
      non-experimental design and mixed PD cohort make this partial for BPD
      specifically.
diagnosis:
- name: Longitudinal psychiatric diagnostic assessment
  description: >-
    Diagnosis is clinical and should evaluate the long-term pattern across
    interpersonal relationships, self-image and identity, affect regulation,
    impulse control, anger, dissociation, paranoia, self-injury, suicidality,
    distress, and functional impairment. A single symptom or crisis
    presentation is insufficient to characterize the enduring pattern.
  diagnosis_term:
    preferred_term: psychiatrist evaluation
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  presence: >-
    A persistent pattern of instability across core personality, affective,
    interpersonal, and behavioral domains, assessed in longitudinal context.
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Borderline personality disorder (BPD) is characterized by a long-term
      pattern of instability of interpersonal relationships, unstable
      self-image, marked impulsivity, and/or affective instability.
    explanation: >-
      The practice-assessment article identifies the longitudinal domains that
      anchor clinical diagnosis.
  - reference: PMID:29795363
    reference_title: Borderline personality disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thus, clinicians need to actively enquire about the central issues of
      interpersonal relations and unstable identity.
    explanation: >-
      The disease primer directly recommends active inquiry into central
      interpersonal and identity features.
- name: Comorbidity, differential, functioning, and safety assessment
  description: >-
    Assess co-occurring psychiatric disorders, episodic mood syndromes,
    trauma-related symptoms, substance use, social and vocational functioning,
    current and past self-injury, suicidal thoughts and behavior, and immediate
    safety needs. Bipolar disorder, PTSD, and other personality disorders must
    be considered rather than assumed to be mutually exclusive.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  presence: >-
    Assessment documents comorbidity, impairment, self-harm and suicide risk,
    and whether overlapping symptoms are better explained by or coexist with
    another disorder.
  evidence:
  - reference: PMID:41613746
    reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      BPD is associated with substantial lifetime burdens and psychosocial
      impairments, including high rates of co-occurring psychiatric disorders;
      disruptions in interpersonal relationships, school, work, and housing;
      and suicide attempts and nonsuicidal self-injury.
    explanation: >-
      The documented comorbidity, functional disruption, and self-harm burden
      supports systematic assessment of these domains.
  - reference: PMID:26401313
    reference_title: "The comorbidity of borderline personality disorder and posttraumatic stress disorder: revisiting the prevalence and associations in a general population sample."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The differential impact of these disorders occurring alone versus in
      comorbid form highlights the importance of diagnosing both BPD and PTSD
      and attending to lifetime comorbidity.
    explanation: >-
      Population evidence directly supports diagnosing comorbid PTSD rather
      than forcing a single-disorder explanation.
differential_diagnoses:
- name: Bipolar Disorder
  description: >-
    Bipolar disorder can overlap with BPD through mood instability, impulsive
    behavior, and recurrent crises.
  distinguishing_features:
  - >-
    Bipolar disorder is distinguished by discrete manic, hypomanic, or
    depressive episodes; BPD typically shows rapid affective reactivity tied to
    interpersonal stressors and persistent personality-function impairment.
  disease_term:
    preferred_term: bipolar disorder
    term:
      id: MONDO:0004985
      label: bipolar disorder
  evidence:
  - reference: PMID:11684137
    reference_title: "Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aim of this study was to compare impulsivity, affective lability and
      intensity in patients with borderline personality and bipolar II disorder
      and in subjects with neither of these diagnoses.
    explanation: >-
      Comparative clinical evidence supports bipolar disorder as a differential
      diagnosis for BPD when affective lability and impulsivity overlap.
- name: Post-Traumatic Stress Disorder
  description: >-
    PTSD and BPD can share trauma history, affective dysregulation, avoidance,
    and dissociative symptoms.
  distinguishing_features:
  - >-
    PTSD centers on trauma re-experiencing, avoidance, and hyperarousal after a
    traumatic event; BPD requires enduring instability in self, relationships,
    affect, and impulse control.
  disease_term:
    preferred_term: post-traumatic stress disorder
    term:
      id: MONDO:0005146
      label: post-traumatic stress disorder
  evidence:
  - reference: PMID:26401313
    reference_title: "The comorbidity of borderline personality disorder and posttraumatic stress disorder: revisiting the prevalence and associations in a general population sample."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The differential impact of these disorders occurring alone versus in
      comorbid form highlights the importance of diagnosing both BPD and PTSD
      and attending to lifetime comorbidity.
    explanation: >-
      Population-based evidence supports assessing PTSD separately when BPD and
      trauma-related symptoms overlap.
- name: Antisocial Personality Disorder
  description: >-
    Antisocial personality disorder can overlap with BPD through impulsivity,
    interpersonal conflict, and risk-taking behavior.
  distinguishing_features:
  - >-
    Antisocial personality disorder is distinguished by pervasive disregard for
    others' rights, deceitfulness, and conduct-problem history; BPD is more
    defined by abandonment sensitivity, affective instability, self-harm, and
    identity disturbance.
  disease_term:
    preferred_term: antisocial personality disorder
    term:
      id: MONDO:0001164
      label: antisocial personality disorder
  evidence:
  - reference: PMID:23514180
    reference_title: Four factors of impulsivity differentiate antisocial and borderline personality disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Impulsivity is a shared criterion for the diagnosis of antisocial and
      borderline personality disorders, and this link may account for the high
      comorbidity rates between the two disorders.
    explanation: >-
      Differential-diagnosis evidence supports antisocial personality disorder
      as a relevant comparator where impulsivity and interpersonal conflict
      overlap.
clinical_trials:
- name: NCT06018272
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >-
    Five-site German randomized trial comparing 12 months of outpatient
    mentalization-based treatment with bona fide psychodynamic or cognitive
    behavioral psychotherapy. Crisis events involving nonsuicidal self-injury
    or suicide attempts are the primary outcome. The registry listed estimated
    enrollment of 304 when checked on 2026-07-24; an active trial record does
    not establish comparative efficacy.
  target_phenotypes:
  - preferred_term: Self-injurious behavior
    term:
      id: HP:0100716
      label: Self-injurious behavior
  - preferred_term: Impairment in personality functioning
    term:
      id: HP:0031466
      label: Impairment in personality functioning
  evidence:
  - reference: clinicaltrials:NCT06018272
    reference_title: "Mentalisierungsbasierte Therapie Versus Bona-fide-Therapie für Patient:Innen Mit Borderline-Persönlichkeitsstörung in Deutschland (MaGnet): Eine Prospektive, Multizentrische Randomisiert-kontrollierte Studie Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany (MAGNET): a Prospective, Multi-centre Randomized Controlled Trial"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The primary objective of this RCT is to investigate whether outpatient
      MBT is more effective in the reduction of crisis events (incidences of
      NSSI and suicide attempts) compared with BFT (namely psychodynamic or
      cognitive-behavioural psychotherapy) in Germany.
    explanation: >-
      The registry directly states the randomized comparison and primary crisis
      outcome.
- name: NCT06458933
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Randomized comparison of the 12-session Sage couple intervention with
    separate supportive individual psychotherapy for a person with BPD and
    their intimate partner. The registry listed 152 couples (304 participants)
    when checked on 2026-07-24. This is an investigational relationship-focused
    intervention, not established care.
  target_phenotypes:
  - preferred_term: Impairment in personality functioning
    term:
      id: HP:0031466
      label: Impairment in personality functioning
  - preferred_term: Emotional lability
    term:
      id: HP:0000712
      label: Emotional lability
  evidence:
  - reference: clinicaltrials:NCT06458933
    reference_title: "A Randomized Controlled Trial Testing Sage: A Couple Intervention for Borderline Personality Disorder"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The study will examine if Sage is more efficacious than SIP in improving
      BPD symptoms (primary outcome), as well as relationship conflict and
      partner mental health (secondary outcomes), as well as a range of other
      outcomes, from pre- to post-intervention, and post-intervention to
      follow-up.
    explanation: >-
      The registry directly describes the experimental couple intervention,
      active comparator, and outcomes.
- name: NCT06446765
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Triple-masked randomized study of one mindfulness-based real-time fMRI
    neurofeedback session versus control neurofeedback, followed in both groups
    by 20 weeks of remote DBT skills training. The registry listed estimated
    enrollment of 150 when checked on 2026-07-24. Neurofeedback augmentation
    remains experimental.
  target_phenotypes:
  - preferred_term: Emotional lability
    term:
      id: HP:0000712
      label: Emotional lability
  - preferred_term: Impulsivity
    term:
      id: HP:0100710
      label: Impulsivity
  evidence:
  - reference: clinicaltrials:NCT06446765
    reference_title: Mindfulness-based Neurofeedback to Augment Dialectical Behavior Therapy (DBT) for Adults With Borderline Personality Disorder (Aim 1)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The purpose of this study is to test the ability of mindfulness-based real
      time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to
      increase the benefits of evidence-based psychotherapy for adults with
      Borderline Personality Disorder (BPD).
    explanation: >-
      The registry directly identifies neurofeedback as an experimental
      augmentation of evidence-based psychotherapy.
discussions:
- discussion_id: gap_bpd_autonomic_stress_causality
  prompt: >-
    Are autonomic, HPA-axis, inflammatory, and cardiometabolic differences
    causal contributors to BPD, consequences of chronic stress and illness, or
    correlates of comorbidity, medication, and health behavior?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Autonomic, Stress-System, and Cardiometabolic Correlates
  rationale: >-
    The available source is a narrative review of heterogeneous human
    associations. Direction, specificity, temporal precedence, and individual
    diagnostic utility remain unestablished.
  evidence:
  - reference: DOI:10.3390/ijms252212286
    reference_title: "Metabolic Dysfunctions, Dysregulation of the Autonomic Nervous System, and Echocardiographic Parameters in Borderline Personality Disorder: A Narrative Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Altered heart rate variability (HRV), reflecting the dysregulation of the
      autonomic nervous system, is associated with some BPD core symptoms, such
      as emotional instability and impulsivity.
    explanation: >-
      The source uses associative language and therefore leaves causal
      direction unresolved.
- discussion_id: gap_bpd_symptomatic_vs_functional_recovery
  prompt: >-
    Which mechanisms and care components convert symptomatic remission into
    durable social and vocational recovery, and prevent subsequent loss of
    recovery?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - progression#Persistent functional vulnerability and possible recurrence
  rationale: >-
    Long follow-up shows that remission of diagnostic symptoms is more common
    than sustained functional recovery, so symptom-only outcomes can overstate
    recovery.
  evidence:
  - reference: PMID:39480146
    reference_title: "Sustained Symptomatic Remission and Recovery and Their Loss Among Patients With Borderline Personality Disorder and Patients With Other Types of Personality Disorders: A 24-Year Prospective Follow-Up Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Taken together, the results of this study suggest that sustained
      symptomatic remission is substantially more common than sustained
      recovery from BPD.
    explanation: >-
      The prospective cohort directly establishes the outcome gap motivating
      this question.
- discussion_id: gap_bpd_comparative_psychotherapy_effectiveness
  prompt: >-
    Which psychotherapy components and delivery formats produce the most
    durable benefits for particular BPD presentations beyond common therapeutic
    factors and bona fide active comparators?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - treatments#Evidence-Based Psychotherapy
  - treatments#Mentalization-Based Treatment
  - clinical_trials#NCT06018272
  rationale: >-
    Psychotherapy is first-line and several modalities improve outcomes, but
    direct active-comparator evidence and treatment-matching evidence remain
    limited. Current trials should not be interpreted as proof of superiority.
  evidence:
  - reference: clinicaltrials:NCT06018272
    reference_title: "Mentalisierungsbasierte Therapie Versus Bona-fide-Therapie für Patient:Innen Mit Borderline-Persönlichkeitsstörung in Deutschland (MaGnet): Eine Prospektive, Multizentrische Randomisiert-kontrollierte Studie Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany (MAGNET): a Prospective, Multi-centre Randomized Controlled Trial"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Yet, randomized-controlled trials (RCT) on MBT in outpatient settings
      compared with bona fide treatment (BFT) are still scarce and none has been
      conducted in Germany.
    explanation: >-
      The trial record explicitly identifies scarcity of MBT comparisons with
      bona fide outpatient treatment.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:41613746
      reference_title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Borderline personality disorder (BPD) is characterized by a long-term
        pattern of instability of interpersonal relationships, unstable
        self-image, marked impulsivity, and/or affective instability.
      explanation: >-
        BPD is a psychiatric disorder; DisMech maps psychiatric disease to the
        neurologic Harrison's chapter grouping.
datasets:
- accession: geo:GSE52222
  title: Aberrant methylation of gene associated CpG sites occurs in borderline personality disorder
  description: Borderline personality disorder (BPD) is a complex psychiatric disease with an increased impact in the last years. While the diagnosis and therapy are well established, little is known on the pathogenesis of borderline personality disorder. Previously, a significant increase in DNA methylation of relevant neuropsychiatric genes in BPD patients has been reported. In our study we performed genome wide methylation analysis and revealed specific CpG sites that exhibited increased methylation in 26 BPD patients compared to 11 healthy controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: METHYLATION
  sample_count: 36
  publication: PMID:24367640
  notes: Identified by GEO DataSets index search for Borderline Personality Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
review_notes: >-
  Re-reviewed from cached primary studies, systematic reviews, and registry
  records; the Falcon deep-research artifact was used only for source
  discovery. Broad inherited and non-shared-environment liability is retained,
  but no single causal gene is asserted. Autonomic, HPA-axis, inflammatory, and
  cardiometabolic findings were collapsed into one provisional correlate node,
  and prior arrows that treated cross-sectional associations as causes were
  removed. Clinical diagnosis remains longitudinal and syndromic; no
  group-level physiological finding is represented as a diagnostic biomarker.
  Pharmacotherapy is not represented as disease-directed first-line treatment
  because the curated evidence supports psychotherapy as first-line and the
  disease primer cautions that misleading pharmacological interventions rarely
  succeed. ClinicalTrials.gov was queried on 2026-07-24; three representative,
  disease-specific active interventional trials were retained, while
  observational studies, broad transdiagnostic records, and redundant
  psychotherapy trials were excluded. Active registry status and phase do not
  imply efficacy. A Monarch D2P audit on 2026-07-24 found no OMIM- or
  Orphanet-backed phenotype rows for MONDO:0001156; three additional clinical
  phenotypes were therefore added only from direct APA publication evidence,
  and all eight curated phenotypes are connected to the clinical pathograph.
references:
- reference: DOI:10.1038/s41380-019-0442-0
  title: "Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population"
  findings: []
- reference: DOI:10.1038/s41380-022-01503-z
  title: "Borderline personality disorder: associations with psychiatric disorders, somatic illnesses, trauma, and adverse behaviors"
  findings: []
- reference: DOI:10.3390/ijms252212286
  title: "Metabolic Dysfunctions, Dysregulation of the Autonomic Nervous System, and Echocardiographic Parameters in Borderline Personality Disorder: A Narrative Review"
  findings: []
- reference: PMID:37902689
  title: "Psychotherapies for the treatment of borderline personality disorder: A systematic review."
  findings: []
- reference: PMID:38420274
  title: "Efficacy of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder: A Systematic Review of Randomized Controlled Trials."
  findings: []
- reference: DOI:10.1186/s12888-024-05865-2
  title: "Mentalization based treatment for a broad range of personality disorders: a naturalistic study"
  findings: []
- reference: PMID:11684137
  title: "Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences."
  findings: []
- reference: PMID:26401313
  title: "The comorbidity of borderline personality disorder and posttraumatic stress disorder: revisiting the prevalence and associations in a general population sample."
  findings: []
- reference: PMID:23514180
  title: Four factors of impulsivity differentiate antisocial and borderline personality disorders.
  findings: []
- reference: PMID:29795363
  title: Borderline personality disorder.
  findings: []
- reference: PMID:30599336
  title: "Long-term clinical and functional course of borderline personality disorder: A meta-analysis of prospective studies."
  findings: []
- reference: PMID:39480146
  title: "Sustained Symptomatic Remission and Recovery and Their Loss Among Patients With Borderline Personality Disorder and Patients With Other Types of Personality Disorders: A 24-Year Prospective Follow-Up Study."
  findings: []
- reference: PMID:41613746
  title: Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
  findings: []
- reference: clinicaltrials:NCT06018272
  title: "Mentalisierungsbasierte Therapie Versus Bona-fide-Therapie für Patient:Innen Mit Borderline-Persönlichkeitsstörung in Deutschland (MaGnet): Eine Prospektive, Multizentrische Randomisiert-kontrollierte Studie Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany (MAGNET): a Prospective, Multi-centre Randomized Controlled Trial"
  findings: []
- reference: clinicaltrials:NCT06458933
  title: "A Randomized Controlled Trial Testing Sage: A Couple Intervention for Borderline Personality Disorder"
  findings: []
- reference: clinicaltrials:NCT06446765
  title: Mindfulness-based Neurofeedback to Augment Dialectical Behavior Therapy (DBT) for Adults With Borderline Personality Disorder (Aim 1)
  findings: []
📚

References & Deep Research

References

16
DOI:10.1038/s41380-019-0442-0
Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population
No top-level findings curated for this source.
DOI:10.1038/s41380-022-01503-z
Borderline personality disorder: associations with psychiatric disorders, somatic illnesses, trauma, and adverse behaviors
No top-level findings curated for this source.
DOI:10.3390/ijms252212286
Metabolic Dysfunctions, Dysregulation of the Autonomic Nervous System, and Echocardiographic Parameters in Borderline Personality Disorder: A Narrative Review
No top-level findings curated for this source.
PMID:37902689
Psychotherapies for the treatment of borderline personality disorder: A systematic review.
No top-level findings curated for this source.
PMID:38420274
Efficacy of Dialectical Behavior Therapy in the Treatment of Borderline Personality Disorder: A Systematic Review of Randomized Controlled Trials.
No top-level findings curated for this source.
DOI:10.1186/s12888-024-05865-2
Mentalization based treatment for a broad range of personality disorders: a naturalistic study
No top-level findings curated for this source.
PMID:11684137
Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences.
No top-level findings curated for this source.
PMID:26401313
The comorbidity of borderline personality disorder and posttraumatic stress disorder: revisiting the prevalence and associations in a general population sample.
No top-level findings curated for this source.
PMID:23514180
Four factors of impulsivity differentiate antisocial and borderline personality disorders.
No top-level findings curated for this source.
PMID:29795363
Borderline personality disorder.
No top-level findings curated for this source.
PMID:30599336
Long-term clinical and functional course of borderline personality disorder: A meta-analysis of prospective studies.
No top-level findings curated for this source.
PMID:39480146
Sustained Symptomatic Remission and Recovery and Their Loss Among Patients With Borderline Personality Disorder and Patients With Other Types of Personality Disorders: A 24-Year Prospective Follow-Up Study.
No top-level findings curated for this source.
PMID:41613746
Practice Assessment Tool for the Care of Patients With Borderline Personality Disorder.
No top-level findings curated for this source.
clinicaltrials:NCT06018272
Mentalisierungsbasierte Therapie Versus Bona-fide-Therapie für Patient:Innen Mit Borderline-Persönlichkeitsstörung in Deutschland (MaGnet): Eine Prospektive, Multizentrische Randomisiert-kontrollierte Studie Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany (MAGNET): a Prospective, Multi-centre Randomized Controlled Trial
No top-level findings curated for this source.
clinicaltrials:NCT06458933
A Randomized Controlled Trial Testing Sage: A Couple Intervention for Borderline Personality Disorder
No top-level findings curated for this source.
clinicaltrials:NCT06446765
Mindfulness-based Neurofeedback to Augment Dialectical Behavior Therapy (DBT) for Adults With Borderline Personality Disorder (Aim 1)
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 38 citations 2026-04-28T09:57:01.038658

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Borderline Personality Disorder
  • MONDO ID: (if available)
  • Category: Psychiatric

Research Objectives

Please provide a comprehensive research report on Borderline Personality Disorder covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Borderline Personality Disorder (BPD): Disease Characteristics Research Report (Psychiatric)

1. Disease information

Overview (current understanding)

Borderline personality disorder (BPD) is a severe psychiatric condition characterized by pervasive instability in emotion regulation, self-image/identity, interpersonal relationships, and behavior, commonly accompanied by impulsivity and recurrent self-harm/suicidality. A recent review summarizes core features consistent with DSM descriptions (e.g., frantic efforts to avoid abandonment; unstable relationships with idealization/devaluation; identity disturbance; impulsivity; recurrent self-harm/suicidality; chronic emptiness; intense anger; and transient stress-related paranoia/dissociation). (azzam2024borderlinepersonalitydisorder pages 2-3)

Key identifiers and ontology mappings

  • ICD-11 model (WHO): ICD-11 no longer uses multiple categorical personality disorder subtypes. Instead, clinicians diagnose Personality Disorder and specify severity (mild/moderate/severe) plus trait domain qualifiers, and may add a “borderline pattern” qualifier. ICD-11 was explicitly designed “to abolish all categories of personality disorder except for the general description of a personality disorder” and then specify “mild,” “moderate,” or “severe.” (mulder2021icd11personalitydisorders pages 2-3)
  • ICD-11 trait domains: Negative affectivity, detachment, dissociality, disinhibition, and anankastia. (mulder2021icd11personalitydisorders pages 2-3, mulder2020theborderlinepattern pages 1-2, pan2024practicalimplicationsof pages 1-2)
  • ICD-11 borderline pattern qualifier: retained as a pragmatic compromise; it “essentially lists the symptoms of” DSM-5 BPD and ICD-10 emotionally unstable personality disorder (borderline type). (mulder2020theborderlinepattern pages 1-2)
  • ICD-10 (historical): Swedish register studies operationalized “emotionally unstable personality disorder” using ICD-10 F60.3. (skoglund2021familialriskand pages 1-2)

MeSH / MONDO / OMIM / Orphanet: Not retrieved in the available evidence set. For knowledge-base population, these should be cross-walked from MeSH and MONDO in a follow-up curation step; BPD is not typically an OMIM/Orphanet monogenic disorder.

Synonyms / alternative names

  • Emotionally unstable personality disorder (ICD-10 terminology; borderline type) (mulder2020theborderlinepattern pages 1-2, skoglund2021familialriskand pages 1-2)
  • Borderline pattern (ICD-11 qualifier) (mulder2021icd11personalitydisorders pages 2-3, mulder2020theborderlinepattern pages 1-2)

Evidence source type

This report integrates aggregated disease-level resources (ICD-11 model papers and reviews) and population-scale individual-level data from Swedish national registers (familial risk, comorbidity, adverse outcomes). (mulder2021icd11personalitydisorders pages 2-3, skoglund2021familialriskand pages 1-2, tate2022borderlinepersonalitydisorder pages 1-2)

2. Etiology

Disease causal factors (multifactorial)

BPD is widely conceptualized as multifactorial, arising from interacting genetic vulnerability and environmental exposures. A 2024 review emphasizes that genetic predispositions (e.g., emotional instability/impulsivity) interact with environmental risks, particularly childhood adversity and attachment disruption. (azzam2024borderlinepersonalitydisorder pages 6-7)

Risk factors

Environmental / developmental risk factors

  • Childhood adversities/trauma (physical, emotional, sexual abuse; neglect; inconsistent caregiving) are frequently reported in BPD and are implicated in disrupted attachment and emotion regulation development. (azzam2024borderlinepersonalitydisorder pages 6-7)
  • Swedish register-based and review evidence notes that a very large proportion of clinically diagnosed BPD have psychiatric comorbidity and adverse outcomes, consistent with high cumulative burden and likely shared risk pathways. (skoglund2021familialriskand pages 2-4, tate2022borderlinepersonalitydisorder pages 1-2)

Genetic risk factors (polygenic)

Family and twin designs support substantial heritability. A Swedish population register study reported heritability 46% (95% CI 39–53), with remaining variance largely due to individually unique environmental factors. (skoglund2021familialriskand pages 1-2)

Direct abstract quote (primary evidence): “Heritability was estimated at 46% (95% CI = 39–53), and the remaining variance was explained by individually unique environmental factors.” (skoglund2021familialriskand pages 2-4)

Familial aggregation shows a gradient with genetic relatedness (hazard ratios in relatives): monozygotic twins HR 11.5, dizygotic twins HR 7.4, full siblings HR 4.7, maternal half-siblings HR 2.1, paternal half-siblings HR 1.3. (skoglund2021familialriskand pages 1-2)

Protective factors

No BPD-specific protective genetic variants or robust protective environmental exposures were identified in the retrieved evidence set. However, long-term work on resilience-related cognitive profiles in relatives suggests potential protective mechanisms at the neurocognitive level (e.g., stronger response inhibition in psychiatrically unaffected relatives), but this is indirect and not a validated protective factor for BPD incidence. (gearin2022spotlightonborderline pages 2-2)

Gene–environment interactions

Direct BPD-specific GxE effect-size estimates were not retrieved in the evidence set. Nonetheless, multiple sources emphasize that trauma/adversity and genetic liability co-occur and likely interact in shaping risk; Swedish data indicate strong familial aggregation and substantial non-shared environment contributions, consistent with a model where individual exposures (including trauma) may interact with inherited liability. (azzam2024borderlinepersonalitydisorder pages 6-7, skoglund2021familialriskand pages 1-2)

3. Phenotypes

Core phenotype spectrum (symptoms and behavioral changes)

Key symptom domains include: * Affective instability / emotion dysregulation (e.g., rapid mood shifts, intense negative affect). (azzam2024borderlinepersonalitydisorder pages 2-3) * Interpersonal instability (e.g., intense/unstable relationships; fear of abandonment). (azzam2024borderlinepersonalitydisorder pages 2-3) * Identity disturbance (unstable self-image, chronic emptiness). (azzam2024borderlinepersonalitydisorder pages 2-3, neri2024borderlinepersonalitydisorder pages 1-2) * Impulsivity / behavioral dysregulation (potentially including substance use, risky behaviors). (azzam2024borderlinepersonalitydisorder pages 2-3) * Self-harm, suicidal ideation/attempts: a major clinical feature; one review notes ~10% may die by suicide. (azzam2024borderlinepersonalitydisorder pages 2-3)

Age of onset and course

Symptoms typically begin in late adolescence/early adulthood (azzam2024borderlinepersonalitydisorder pages 2-3), with a narrative psychotherapy review also noting emergence in adolescence (often after age 12). (neri2024borderlinepersonalitydisorder pages 1-2)

Course heterogeneity is emphasized: impulsivity-related symptoms (self-harm, suicidality) may remit earlier, whereas chronic affective/interpersonal problems may persist and functional impairment can remain even when diagnostic criteria remit. (neri2024borderlinepersonalitydisorder pages 1-2)

Comorbidity and adverse outcomes (quantitative)

A large Swedish nationwide register study (n ≈ 2 million; 12,175 diagnosed BPD) found markedly elevated risks across psychiatric disorders, somatic illnesses, trauma, and adverse behaviors. Examples: * Anxiety disorders cumulative incidence 33.13% (95% CI 31.48–34.73). (tate2022borderlinepersonalitydisorder pages 1-2) * Psychotic disorders HR 24.48 (95% CI 23.14–25.90). (tate2022borderlinepersonalitydisorder pages 1-2) * Self-harm HR 17.72 (95% CI 17.27–18.19). (tate2022borderlinepersonalitydisorder pages 1-2) * Violent crime victimization HR 7.65 (95% CI 7.25–8.06). (tate2022borderlinepersonalitydisorder pages 1-2) * Epilepsy HR 3.38 (95% CI 3.08–3.70). (tate2022borderlinepersonalitydisorder pages 1-2)

Suggested HPO terms (examples for knowledge-base mapping)

HPO codes were not retrieved from HPO directly in the evidence set; below are suggested mappings for curation: * Affective lability / mood swings (e.g., HP:0000728 Mood swings — verify in HPO) * Impulsivity (HP:0000733 Impulsivity — verify) * Self-injurious behavior (HP:0100716 Self-injurious behavior — verify) * Suicidal ideation (HP:0031586 Suicidal ideation — verify) * Abnormal social relationships / interpersonal dysfunction (verify HPO term) * Chronic feelings of emptiness (may require phenotypic proxy term)

4. Genetic / molecular information

Genetic architecture

BPD is polygenic rather than a monogenic Mendelian disorder in the retrieved evidence. The strongest quantitative evidence is familial aggregation and heritability in Swedish registries (heritability ~46%). (skoglund2021familialriskand pages 1-2)

Notable genetic correlations / shared liability

A Swedish nationwide study showed extremely strong co-occurrence and familial co-aggregation between ADHD and BPD: * Individuals with ADHD had adjusted OR 19.4 (95% CI 18.6–20.4) for also having BPD. (kujahalkola2021doborderlinepersonality pages 1-2) * Familial co-aggregation: e.g., full siblings of ADHD cases had aOR 2.8 (95% CI 2.6–3.1) for BPD. (kujahalkola2021doborderlinepersonality pages 1-2)

Epigenetics / non-coding RNA (recent developments)

A 2023 study connects a microRNA signal to brain morphology and suicidal ideation recovery in BPD. Direct abstract quote: “MicroRNA-124-3p (miR-124-3p) was recently identified in a Genome-Wide Association Study as likely associated with BPD.” ()

In that inpatient sample, genes targeted by miR-124-3p were co-expressed in the left globus pallidus, which was smaller in BPD than psychiatric controls, and smaller volume correlated with poorer recovery from suicidal ideation. ()

Suggested GO / CL / UBERON terms (mechanism-linked suggestions)

Not explicitly enumerated in the evidence set; suggested for curation based on described systems: * UBERON: amygdala; prefrontal cortex; anterior cingulate cortex; globus pallidus (NCT07197502 chunk 1, NCT06626789 chunk 2) * CL: cortical pyramidal neuron; GABAergic interneuron; microglia (neuroinflammation context) (bozzatello2024metabolicdysfunctionsdysregulation pages 8-9) * GO Biological Process (examples): regulation of emotional behavior; response to stress; synaptic signaling; neuroinflammatory response; hypothalamic–pituitary–adrenal axis process (bozzatello2024metabolicdysfunctionsdysregulation pages 8-9)

5. Environmental information

Environmental factors and lifestyle factors

Evidence in the retrieved set emphasizes chronic stress/trauma as major environmental inputs into BPD symptom development and maintenance. (azzam2024borderlinepersonalitydisorder pages 6-7)

A 2024 review highlights that BPD is associated with metabolic dysfunction and cardiovascular risk, with contributing factors including obesity and childhood trauma, and with inflammatory marker elevations such as CRP/hs-CRP described in the literature. (bozzatello2024metabolicdysfunctionsdysregulation pages 8-9)

Infectious agents

No BPD-specific infectious etiology was identified in the retrieved evidence.

6. Mechanism / pathophysiology

Working model causal chain (integrative)

Upstream: inherited liability (polygenic; ~46% heritability) + individual-specific environmental exposures (including childhood adversity) → (skoglund2021familialriskand pages 1-2, azzam2024borderlinepersonalitydisorder pages 6-7)

Intermediate mechanisms (proposed and partially evidenced): * Disrupted attachment/mentalizing and emotion regulation capacities (azzam2024borderlinepersonalitydisorder pages 6-7) * Autonomic nervous system dysregulation and stress physiology changes, including HPA-axis alterations described in a 2024 review (qualitative) (bozzatello2024metabolicdysfunctionsdysregulation pages 8-9) * Neurobiological circuit targets for treatment trials: amygdala–ventrolateral prefrontal circuits (rTMS and neurofeedback trials) (NCT07197502 chunk 1, NCT06626789 chunk 2) * Epigenetic/noncoding regulation and basal ganglia involvement: miR-124-3p target-gene co-expression implicating globus pallidus morphology associated with suicidal ideation recovery. ()

Downstream: clinical manifestations (affective instability, impulsivity, unstable relationships, self-harm/suicidality) and high comorbidity/adverse outcomes. (azzam2024borderlinepersonalitydisorder pages 2-3, tate2022borderlinepersonalitydisorder pages 1-2)

Immune/inflammatory and physiological findings (recent)

A 2024 narrative review synthesizes evidence that BPD can be associated with increased cardiometabolic risk and inflammatory biomarkers (e.g., CRP/hs-CRP) and autonomic dysregulation (e.g., HRV alterations), though effect sizes were not extractable from the provided excerpt. (bozzatello2024metabolicdysfunctionsdysregulation pages 8-9)

7. Anatomical structures affected

BPD is a psychiatric disorder without primary peripheral organ pathology, but implicated neuroanatomy/circuits in the retrieved evidence includes: * Amygdala–ventrolateral prefrontal cortex (vlPFC) circuitry (targeted by rTMS and neurofeedback trials). (NCT07197502 chunk 1, NCT06626789 chunk 2) * Globus pallidus (reduced volume in inpatients with BPD vs psychiatric controls, in miR-124-3p target-gene analysis context). ()

Suggested UBERON terms for curation: amygdala, ventrolateral prefrontal cortex, globus pallidus.

8. Temporal development

Onset

Most commonly late adolescence/early adulthood. (azzam2024borderlinepersonalitydisorder pages 2-3)

Progression / remission

BPD can show symptom remission over years (especially impulsive/self-harm symptoms), but functional impairment may persist; course is heterogeneous. (neri2024borderlinepersonalitydisorder pages 1-2)

9. Inheritance and population

Epidemiology (quantitative)

  • General population prevalence estimates in recent reviews are ~1–2% (azzam2024borderlinepersonalitydisorder pages 2-3) and ~1.6% (neri2024borderlinepersonalitydisorder pages 1-2).
  • Clinical settings prevalence estimates in reviews: 15–20% in psychiatric settings (azzam2024borderlinepersonalitydisorder pages 2-3), ~20% clinical populations, ~10% ambulatory, ~25% hospitalized. (neri2024borderlinepersonalitydisorder pages 1-2)

Sex ratio

A review reports approximately 3:1 female-to-male ratio. (azzam2024borderlinepersonalitydisorder pages 2-3) Swedish registers similarly show strong female predominance among clinically diagnosed cases (~85%). (tate2022borderlinepersonalitydisorder pages 1-2, skoglund2021familialriskand pages 2-4)

Genetic etiology / inheritance model

Evidence supports multifactorial/polygenic inheritance with substantial heritability. * Heritability: 46% (95% CI 39–53). (skoglund2021familialriskand pages 1-2)

10. Diagnostics

Clinical criteria and structured assessment

  • DSM-style diagnostic symptom domains are summarized in recent reviews (abandonment fears, relationship instability, identity disturbance, impulsivity, self-harm/suicidality, emptiness, anger, transient paranoia/dissociation). (azzam2024borderlinepersonalitydisorder pages 2-3)
  • ICD-11 approach: diagnose personality disorder and rate severity and traits; optionally add the borderline pattern qualifier, which is close to the DSM borderline definition. (mulder2021icd11personalitydisorders pages 2-3, mulder2020theborderlinepattern pages 1-2)

Biomarkers and tests

No validated laboratory biomarker is established for diagnosis in the retrieved evidence. A 2024 review discusses candidate physiological markers (e.g., CRP/hs-CRP, autonomic measures/HRV, echocardiographic strain measures) as part of cardiometabolic risk profiling rather than diagnostic biomarkers. (bozzatello2024metabolicdysfunctionsdysregulation pages 8-9)

Differential diagnosis considerations (high-level)

Diagnostic issues include overlap with trauma-related syndromes and other mood disorders; a 2024 review highlights overlap with complex PTSD and emphasizes that trauma is common but not universal and not the sole cause. (azzam2024borderlinepersonalitydisorder pages 6-7)

11. Outcome / prognosis

Mortality and suicide

BPD carries substantial suicide mortality. A 2024 review reports that roughly 10% may die by suicide and emphasizes common recurrent self-harm/suicidality. (azzam2024borderlinepersonalitydisorder pages 2-3)

Morbidity and functional outcomes

Register data demonstrate BPD diagnosis as a marker of vulnerability for multiple negative outcomes (psychiatric, somatic, trauma, adverse behaviors), including very high self-harm risk (HR ~17.7) and high psychiatric comorbidity burden. (tate2022borderlinepersonalitydisorder pages 1-2)

12. Treatment

Evidence-based psychotherapies (core of care)

Multiple evidence-based psychotherapies are emphasized as key treatments, including Dialectical Behavior Therapy (DBT), Mentalization-Based Treatment (MBT), Schema Therapy, and Transference-Focused Psychotherapy (TFP). (azzam2024borderlinepersonalitydisorder pages 2-3, azzam2024borderlinepersonalitydisorder pages 9-10, neri2024borderlinepersonalitydisorder pages 1-2)

A narrative review concludes that psychotherapy is the main treatment and “there is no single form of psychotherapy that can fully treat BPD,” but highlights DBT and schema therapy as especially effective for impulsive/self-injurious symptoms and comorbidity management. (neri2024borderlinepersonalitydisorder pages 1-2)

DBT evidence base (recent synthesis): a 2024 systematic review of RCTs identified 18 RCTs (total 1,755 participants) and reported that trials often target self-injury, suicidal ideation, emergency visits, and hospitalizations; short-term and standard DBT improved suicidality with small-to-moderate effect sizes lasting up to 24 months post-treatment in many studies. ()

MBT evidence (real-world implementation): a 2024 naturalistic MBT study (n=46, BPD n=25) found MBT enrollment associated with decreased psychiatric symptoms and improved functioning (all p’s ≤ .01); mentalizing capacity improved (e.g., d=0.68 on TAS; d=1.46 on SCORS), but causal inference is limited due to non-experimental design. (rizzi2024mentalizationbasedtreatment pages 1-2)

Pharmacotherapy (adjunctive)

Recent reviews emphasize pharmacotherapy as adjunctive (symptom-targeted, comorbidity-focused), not a primary treatment for core BPD pathology. Agents commonly used include SSRIs, mood stabilizers, and atypical antipsychotics. (azzam2024borderlinepersonalitydisorder pages 2-3, neri2024borderlinepersonalitydisorder pages 1-2)

Current applications and real-world implementations

  • Specialized, manualized psychotherapies require trained clinicians and resources; barriers to access are noted, supporting stepped-care and service design work. (neri2024borderlinepersonalitydisorder pages 1-2, azzam2024borderlinepersonalitydisorder pages 9-10)
  • ICD-11 dimensional PD diagnosis is being positioned for broader clinical usability, including adolescence, with the borderline pattern qualifier retained in part to support continuity and identify people likely to benefit from psychotherapy. (pan2024practicalimplicationsof pages 1-2)

Ongoing and recent clinical trials (ClinicalTrials.gov)

Recent real-world implementations and experimental therapeutics include neuromodulation, neurofeedback, trauma-focused interventions, and pharmacologic proof-of-concept:

  • rTMS (circuit-based, vlPFC–amygdala targeting)
  • NCT07197502 (UCLA; recruiting; start 2025-03-01; n=30; randomized single-masked crossover; primary outcomes BSL-23, CGI-BPD, DERS). URL: https://clinicaltrials.gov/study/NCT07197502 (NCT07197502 chunk 1)

  • NCT07223619 (UCLA; active not recruiting; start 2024; n=20; single-group; individualized vlPFC targeting via resting-state fMRI; tasks include delay discounting and cognitive reappraisal of social exclusion pain). URL: https://clinicaltrials.gov/study/NCT07223619 (NCT07223619 chunk 1)

  • Real-time fMRI neurofeedback (amygdala down-regulation)

  • NCT06626789 (BrainSTEADy; planned total n=164; RCT vs sham; includes health-economic outcomes such as QALYs/AQoL-6D). URL: https://clinicaltrials.gov/study/NCT06626789 (NCT06626789 chunk 2)

  • Trauma-focused psychotherapy

  • NCT06493708 (EMDR; recruiting; start 2024-10-01; n=56; randomized factorial; primary outcome ZAN-BPD; multiple symptom/regulation measures across 18 weeks). URL: https://clinicaltrials.gov/study/NCT06493708 (NCT06493708 chunk 1)

  • DBT mechanisms / biomarker-rich designs

  • NCT06882330 (NeuroDBT; completed; n=106; longitudinal controlled DBT study with clinical outcomes and fMRI/EEG/HRV measures). URL: https://clinicaltrials.gov/study/NCT06882330 (NCT06882330 chunk 1, NCT06882330 chunk 2)

  • Pharmacologic proof-of-concept

  • NCT06759298 (methylphenidate/Concerta vs placebo; not yet recruiting; start 2025-01-15; n=60; primary outcomes impulsivity and stress). URL: https://clinicaltrials.gov/study/NCT06759298 (NCT06759298 chunk 1)

  • Adjunctive/feasibility interventions

  • NCT07476300 (auricular acupuncture feasibility pilot; not yet recruiting; start 2026-04-15; n=15; NADA protocol). URL: https://clinicaltrials.gov/study/NCT07476300 (NCT07476300 chunk 1)

Suggested MAXO terms (examples)

MAXO IDs not retrieved directly; suggested actions for curation: * Dialectical behavior therapy (DBT) * Mentalization-based therapy (MBT) * Schema therapy * Psychodynamic psychotherapy / transference-focused psychotherapy * Repetitive transcranial magnetic stimulation (rTMS) * Real-time fMRI neurofeedback * Eye movement desensitization and reprocessing (EMDR)

13. Prevention

Primary prevention is not well-established for BPD in the retrieved evidence. However, ICD-11 and early-intervention literature emphasize earlier identification (including in adolescence) and timely access to evidence-based psychotherapy as a pragmatic prevention strategy for downstream harms (self-harm, hospitalization, chronic disability). (pan2024practicalimplicationsof pages 1-2)

14. Other species / natural disease

No naturally occurring “BPD” diagnosis exists in non-human species in the retrieved evidence set; translational relevance is typically via endophenotypes (impulsivity, stress reactivity, social behavior) rather than direct disease homology.

15. Model organisms

The retrieved evidence set did not include validated animal models of BPD. Related translational approaches focus on circuits/behaviors (e.g., stress vulnerability, impulsivity) and neuromodulation targets; these are better represented as dimensional constructs rather than a single disease model.

Summary artifact

The following table compiles high-yield quantitative facts and classification identifiers extracted from the retrieved evidence.

Topic Key finding (with numbers) Source (first author, year) URL Evidence type Citation ID placeholder
Definition / core features BPD is characterized by pervasive instability in emotional regulation, self-image, interpersonal relationships, and behavior; core DSM-style features include abandonment fears, unstable idealization/devaluation, identity disturbance, impulsivity, recurrent self-harm/suicidality, chronic emptiness, anger dyscontrol, and transient paranoia/dissociation Azzam, 2024 https://doi.org/10.7759/cureus.75893 Narrative review (azzam2024borderlinepersonalitydisorder pages 2-3)
Prevalence in general population Reported prevalence is about 1–2% of the general population; another recent review reports ~1.6% Azzam, 2024; Neri, 2024 https://doi.org/10.7759/cureus.75893 ; https://doi.org/10.22543/2392-7674.1500 Review (azzam2024borderlinepersonalitydisorder pages 2-3, neri2024borderlinepersonalitydisorder pages 1-2)
Prevalence in clinical settings Reported prevalence rises to 15–20% in psychiatric settings; review also notes ~20% in clinical populations, ~10% of ambulatory patients, and ~25% of hospitalized patients Azzam, 2024; Neri, 2024 https://doi.org/10.7759/cureus.75893 ; https://doi.org/10.22543/2392-7674.1500 Review (azzam2024borderlinepersonalitydisorder pages 2-3, neri2024borderlinepersonalitydisorder pages 1-2)
Sex ratio Female-to-male ratio reported as approximately 3:1 in clinical samples; a large Swedish cohort found 85.3% female among diagnosed cases Azzam, 2024; Tate, 2022 https://doi.org/10.7759/cureus.75893 ; https://doi.org/10.1038/s41380-022-01503-z Review; register study (azzam2024borderlinepersonalitydisorder pages 2-3)
Typical onset Symptoms typically begin in late adolescence / early adulthood; one review notes emergence in adolescence, often after age 12 Azzam, 2024; Neri, 2024 https://doi.org/10.7759/cureus.75893 ; https://doi.org/10.22543/2392-7674.1500 Review (azzam2024borderlinepersonalitydisorder pages 2-3, neri2024borderlinepersonalitydisorder pages 1-2)
Suicide mortality Approximately 10% of people with BPD may die by suicide; chronic self-harm and suicide attempts are common Azzam, 2024 https://doi.org/10.7759/cureus.75893 Review (azzam2024borderlinepersonalitydisorder pages 2-3)
ICD-11 diagnostic model ICD-11 replaces categorical PD subtypes with a dimensional model: diagnosis of personality disorder is specified by severity (mild, moderate, severe) plus trait domains; clinicians may add a borderline pattern qualifier Mulder, 2021 https://doi.org/10.3389/fpsyt.2021.655548 Review / classification commentary (zheleva2024experiencesofpatients pages 10-15)
ICD-11 borderline pattern note Borderline pattern in ICD-11 is treated as an additional qualifier rather than a standalone disorder category; it maps mainly onto negative affective, dissocial, and disinhibited domains Mulder, 2020 https://doi.org/10.1177/0004867420951608 Classification analysis (zheleva2024experiencesofpatients pages 10-15)
Key genetic statistic In a Swedish population register study of 1,851,755 individuals, 11,665 received a BPD diagnosis; heritability was estimated at 46% (95% CI 39–53), with remaining variance explained by individually unique environmental factors Skoglund, 2021 https://doi.org/10.1038/s41380-019-0442-0 Population register study (zheleva2024experiencesofpatients pages 10-15)

Table: This table compiles high-yield identifiers and quantitative disease characteristics for borderline personality disorder, including prevalence, onset, suicide risk, ICD-11 classification notes, and heritability. It is useful as a quick reference for populating structured knowledge-base fields.

Key expert/authoritative perspectives (2023–2024 emphasis)

  • ICD-11 experts describe the PD model as a major shift: from categorical types to severity+traits, with a retained borderline pattern qualifier largely for continuity with established clinical practice and psychotherapy evidence bases. (mulder2021icd11personalitydisorders pages 2-3, pan2024practicalimplicationsof pages 1-2, mulder2020theborderlinepattern pages 1-2)
  • Contemporary clinical reviews consistently position psychotherapy as first-line and pharmacotherapy as adjunctive for symptom clusters and comorbidities. (azzam2024borderlinepersonalitydisorder pages 2-3, neri2024borderlinepersonalitydisorder pages 1-2)

Limitations of this report

  • DSM-5 text, ICD-11 official code strings, MeSH/MONDO identifiers, and many HPO/GO/CL/UBERON numeric IDs were not directly retrievable from the current evidence set; ontology term suggestions above are therefore non-cited placeholders for expert curation.
  • Biomarker findings (inflammation/HRV/HPA axis) in the retrieved evidence were largely narrative/qualitative without extractable pooled effect sizes. (bozzatello2024metabolicdysfunctionsdysregulation pages 8-9)

References

  1. (azzam2024borderlinepersonalitydisorder pages 2-3): Saif Azzam, Rahma Almari, Karees Khattab, Ammar Badr, Arwa R Balawi, Rana Haddad, Rawan Almasri, and Giustino Varrassi. Borderline personality disorder: a comprehensive review of current diagnostic practices, treatment modalities, and key controversies. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75893, doi:10.7759/cureus.75893. This article has 11 citations.

  2. (mulder2021icd11personalitydisorders pages 2-3): Roger T. Mulder. Icd-11 personality disorders: utility and implications of the new model. Frontiers in Psychiatry, May 2021. URL: https://doi.org/10.3389/fpsyt.2021.655548, doi:10.3389/fpsyt.2021.655548. This article has 131 citations.

  3. (mulder2020theborderlinepattern pages 1-2): Roger T Mulder, L John Horwood, and Peter Tyrer. The borderline pattern descriptor in the international classification of diseases, 11th revision: a redundant addition to classification. Australian & New Zealand Journal of Psychiatry, 54:1095-1100, Sep 2020. URL: https://doi.org/10.1177/0004867420951608, doi:10.1177/0004867420951608. This article has 39 citations and is from a peer-reviewed journal.

  4. (pan2024practicalimplicationsof pages 1-2): Bing Pan and Wei Wang. Practical implications of icd-11 personality disorder classifications. BMC Psychiatry, Mar 2024. URL: https://doi.org/10.1186/s12888-024-05640-3, doi:10.1186/s12888-024-05640-3. This article has 27 citations and is from a domain leading peer-reviewed journal.

  5. (skoglund2021familialriskand pages 1-2): Charlotte Skoglund, Annika Tiger, Christian Rück, Predrag Petrovic, Philip Asherson, Clara Hellner, David Mataix-Cols, and Ralf Kuja-Halkola. Familial risk and heritability of diagnosed borderline personality disorder: a register study of the swedish population. Molecular Psychiatry, 26:999-1008, Jun 2021. URL: https://doi.org/10.1038/s41380-019-0442-0, doi:10.1038/s41380-019-0442-0. This article has 139 citations and is from a highest quality peer-reviewed journal.

  6. (tate2022borderlinepersonalitydisorder pages 1-2): Ashley E. Tate, Hanna Sahlin, Shengxin Liu, Yi Lu, Sebastian Lundström, Henrik Larsson, Paul Lichtenstein, and Ralf Kuja-Halkola. Borderline personality disorder: associations with psychiatric disorders, somatic illnesses, trauma, and adverse behaviors. Molecular Psychiatry, 27:2514-2521, Mar 2022. URL: https://doi.org/10.1038/s41380-022-01503-z, doi:10.1038/s41380-022-01503-z. This article has 77 citations and is from a highest quality peer-reviewed journal.

  7. (azzam2024borderlinepersonalitydisorder pages 6-7): Saif Azzam, Rahma Almari, Karees Khattab, Ammar Badr, Arwa R Balawi, Rana Haddad, Rawan Almasri, and Giustino Varrassi. Borderline personality disorder: a comprehensive review of current diagnostic practices, treatment modalities, and key controversies. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75893, doi:10.7759/cureus.75893. This article has 11 citations.

  8. (skoglund2021familialriskand pages 2-4): Charlotte Skoglund, Annika Tiger, Christian Rück, Predrag Petrovic, Philip Asherson, Clara Hellner, David Mataix-Cols, and Ralf Kuja-Halkola. Familial risk and heritability of diagnosed borderline personality disorder: a register study of the swedish population. Molecular Psychiatry, 26:999-1008, Jun 2021. URL: https://doi.org/10.1038/s41380-019-0442-0, doi:10.1038/s41380-019-0442-0. This article has 139 citations and is from a highest quality peer-reviewed journal.

  9. (gearin2022spotlightonborderline pages 2-2): Priya F. Gearin. Spotlight on borderline personality disorder: history, genetics, and neurobiology. The Brown University Child and Adolescent Behavior Letter, 38:1-4, Aug 2022. URL: https://doi.org/10.1002/cbl.30652, doi:10.1002/cbl.30652. This article has 0 citations.

  10. (neri2024borderlinepersonalitydisorder pages 1-2): Marina Neri, Antonino Reitano, Lavinia Rinnone, Antonio Bruno, Fabrizio Turiaco, Felicia Matilde Ferreri, Carmela Mento, Maria Rosaria Anna Muscatello, and Fiammetta Iannuzzo. Borderline personality disorder: a narrative review on effective psychotherapies. Journal of Mind and Medical Sciences, 11:267-276, Oct 2024. URL: https://doi.org/10.22543/2392-7674.1500, doi:10.22543/2392-7674.1500. This article has 1 citations.

  11. (kujahalkola2021doborderlinepersonality pages 1-2): Ralf Kuja-Halkola, Kristina Lind Juto, Charlotte Skoglund, Christian Rück, David Mataix-Cols, Ana Pérez-Vigil, Johan Larsson, Clara Hellner, Niklas Långström, Predrag Petrovic, Paul Lichtenstein, and Henrik Larsson. Do borderline personality disorder and attention-deficit/hyperactivity disorder co-aggregate in families? a population-based study of 2 million swedes. Molecular Psychiatry, 26:341-349, Oct 2021. URL: https://doi.org/10.1038/s41380-018-0248-5, doi:10.1038/s41380-018-0248-5. This article has 55 citations and is from a highest quality peer-reviewed journal.

  12. (NCT07197502 chunk 1): Andrew F. Leuchter. Treatment of Borderline Personality Disorder With rTMS. University of California, Los Angeles. 2025. ClinicalTrials.gov Identifier: NCT07197502

  13. (NCT06626789 chunk 2): Brain Signal Training to Enhance Affect Down-regulation. Central Institute of Mental Health, Mannheim. 2025. ClinicalTrials.gov Identifier: NCT06626789

  14. (bozzatello2024metabolicdysfunctionsdysregulation pages 8-9): Paola Bozzatello, Giacomo Marin, Giulio Gabriele, Claudio Brasso, Paola Rocca, and Silvio Bellino. Metabolic dysfunctions, dysregulation of the autonomic nervous system, and echocardiographic parameters in borderline personality disorder: a narrative review. International Journal of Molecular Sciences, 25:12286, Nov 2024. URL: https://doi.org/10.3390/ijms252212286, doi:10.3390/ijms252212286. This article has 10 citations.

  15. (azzam2024borderlinepersonalitydisorder pages 9-10): Saif Azzam, Rahma Almari, Karees Khattab, Ammar Badr, Arwa R Balawi, Rana Haddad, Rawan Almasri, and Giustino Varrassi. Borderline personality disorder: a comprehensive review of current diagnostic practices, treatment modalities, and key controversies. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75893, doi:10.7759/cureus.75893. This article has 11 citations.

  16. (rizzi2024mentalizationbasedtreatment pages 1-2): Endang Rizzi, Jonas Gijs Weijers, Coriene ten Kate, and Jean-Paul Selten. Mentalization based treatment for a broad range of personality disorders: a naturalistic study. BMC Psychiatry, Jun 2024. URL: https://doi.org/10.1186/s12888-024-05865-2, doi:10.1186/s12888-024-05865-2. This article has 10 citations and is from a domain leading peer-reviewed journal.

  17. (NCT07223619 chunk 1): Andrew F. Leuchter. PILOT Phase: BPD Study. University of California, Los Angeles. 2024. ClinicalTrials.gov Identifier: NCT07223619

  18. (NCT06493708 chunk 1): Antonio Vita. Effectiveness of EMDR in Borderline Personality Disorder. Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia. 2024. ClinicalTrials.gov Identifier: NCT06493708

  19. (NCT06882330 chunk 1): Neural Mechanisms of Dialectical Behavioral Therapy in Patients with Borderline Personality Disorder. Masarykova Univerzita. 2020. ClinicalTrials.gov Identifier: NCT06882330

  20. (NCT06882330 chunk 2): Neural Mechanisms of Dialectical Behavioral Therapy in Patients with Borderline Personality Disorder. Masarykova Univerzita. 2020. ClinicalTrials.gov Identifier: NCT06882330

  21. (NCT06759298 chunk 1): Osama Ibrahim Younes. The Effects of Methylphenidate on Symptomatology in Individuals With Borderline Personality Disorder. Tanta University. 2025. ClinicalTrials.gov Identifier: NCT06759298

  22. (NCT07476300 chunk 1): Jenny Gentizon. Pilot Study on Auricular Acupuncture in Hospitalized Adults With Borderline Personality Disorder. Jenny Gentizon. 2026. ClinicalTrials.gov Identifier: NCT07476300

  23. (zheleva2024experiencesofpatients pages 10-15): N Zheleva. Experiences of patients with borderline personality disorder in mentalization based psychoeducation groups: a qualitative study. Unknown journal, 2024.